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The aim of this thesis was to analyze, 
by using immunological methods, 
whether gliadin-specific immune 
responses can be detected prior to the 
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in genetically susceptible children 
may be possible by monitoring tTGA 
and anti-DGP antibodies whereas 
monitoring peripheral blood gliadin-
specific T-cell responses did not 
enhance early diagnosis. Anti-DGP 
antibodies may be the first marker 
of celiac disease in a majority of 
pediatric patients.
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VABSTRACT
Celiac disease is a chronic autoimmune enteropathy caused by dietary gluten, a protein 
rich of gliadin peptides found in wheat and related cereals, in genetically predisposed 
individuals. Celiac disease can be established in all age groups. The typical symptoms of 
celiac disease are diarhoea, runny stools, abdominal distension, weight loss and growth 
disturbance and delayed puberty in children. As a consequence of the malabsorption ane-
mia and ostheoporosis may follow. It is known that some of the affected patients may 
have unspecific symptoms, or they may be even asymptomatic. The primary screening of 
celiac disease is mainly based on IgA class tissue transglutaminase autoantibody (tTGA) 
measurement and the diagnosis is confirmed by the identification of typical histolog-
ical changes, crypt hyperplasia and villous atrophy, in the small intestinal mucosa by 
duodenal biopsy. Although serological screening has a central role in the diagnosis of 
celiac disease, it is known that the T-cell mediated inflammatory process of the intestinal 
mucosa has already begun when celiac disease-associated antibodies appear. The aim 
of this thesis was to analyze, by using immunological methods, whether gliadin-specific 
immune responses can be detected prior to the damage of the intestinal mucosa and the 
development of the clinical disease. 
Peripheral blood gliadin-specific CD4+ T-cell responses were detected in over half of 
the children with newly diagnosed celiac disease in study I. In children with celiac dis-
ease T-cell responses were detected more often to deamidated gliadin (gTG) than to na-
tive gliadin whereas the responses to deamidated and native gliadin did not differ in 
healthy controls. 
The detection of antibodies to synthetic deamidated gliadin peptide (anti-DGP) can be 
used in diagnosis of celiac disease in young children. In study II we demonstrated that the 
time-resolved immunofluorometric (TR-IFMA) assay for detecting anti-DGP performed 
with both a high sensitivity and specificity in the diagnosis of celiac disease in pediatric 
patients. 
In study III newborn children were screened for HLA-DQ2, encoded by HLA-DQA1*05 
and -DQB1*02 alleles and were followed prospectively by screening for tTGA and 
anti-DGP antibodies and peripheral blood gliadin-specific T-cell responses until 3 or 4 
years of age. The cumulative incidence of tTGA seropositivity until the age of 4 years 
was 6.5% and the final incidence of celiac disease was 3.1%. All except one of the children 
in the follow-up study were diagnosed through the serological screening without pre-
vious clinical suspicion of celiac disease. We demonstrated both retrospectively (II) and 
prospectively (III) that in a majority of the children with celiac disease specifically IgG 
anti-DGP antibodies appeared a median one year earlier than tTGA seropositivity. In the 
prospective follow-up (III) peripheral blood gliadin-specific T-cell responses were rela-
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tively common at the age of 9 and 12 months but the proportion of the positive responses 
decreased during the follow-up to the similar lever detected in slightly older healthy 
control children in study I. The common appearance of T-cell responses to gTG may be 
related with an early immunization to dietary gluten, which in most cases does not lead 
either to the development of celiac disease-related antibodies or the clinical onset of the 
celiac disease. 
In conclusion, the results of this work indicate that detection of celiac disease earlier 
than with current approaches may be possible by monitoring tTGA and anti-DGP anti-
bodies frequently in genetically susceptible children whereas the monitoring of periph-
eral blood gliadin-specific T-cell responses does not enhance early diagnosis. Moreover, 
anti-DGP antibodies may be the first marker of celiac disease in a majority of pediatric 
patients. 
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TIIVISTELMÄ
Keliakia on ravinnon gliadiinin aiheuttama krooninen, autoimmuuni suolistosairaus 
geneettisesti alttiilla henkilöillä. Keliakiaa esiintyy kaikissa ikäryhmissä. Sen tyypillisiä 
oireita ovat mm. ripuli, löysät ulosteet, ilmavaivat, painon lasku ja lapsilla kasvun hi-
dastuminen tai puberteetin viivästyminen. Suoliston imeytymishäiriön seurauksena voi 
ilmaantua anemiaa ja osteoporoosia. Keliakian seulonta perustuu pääosin seerumin IgA 
luokan kudostransglutaminaasivasta-aineiden määritykseen, ja diagnoosi varmistetaan 
ohutsuolen biopsialla, jossa keliakialle tyypilliset muutokset ovat villusatrofia ja kryp-
tahyperplasia. Vasta-aineiden seulonnalla on keskeinen merkitys keliakian diagnosoin-
nissa mutta toisaalta tiedetään, että T-soluvälitteinen ohutsuolen tulehdusreaktio on jo 
käynnistynyt keliakialle spesifisten vasta-aineiden ilmaantuessa. Lisäksi tiedetään, että 
osalla sekä aikuis- että lapsipotilaista oireet voivat olla epäspesifisiä, kuten niveloireita 
tai ataksiaa ja osa potilaista voi olla täysin oireettomia. Keliakian toistaiseksi ainoa hoi-
tomuoto on elinikäinen gluteeniton ruokavalio. Tämän väitöstutkimuksen tarkoituksena 
oli selvittää, voidaanko immunivastetta havaita jo ennen ohutsuolen tuhoutumista ja klii-
nisen taudin puhkeamista immunologisilla testeillä.
Osatyössä I perifeerisen veren gliadiinispesifisiä T-soluvasteita havaittiin hieman yli 
puolella lapsista, joilla oli juuri diagnosoitu keliakia.  Keliakiaan sairastuneilla lapsilla 
T-soluvasteita esiintyi merkitsevästi enemmän deamidoitua gliadiinia kohtaan, kun taas 
terveillä mutta keliakialle geneettisesti alttiilla kontrollilapsilla T-soluvasteet olivat yhtä 
yleisiä deamidoitua ja natiivia gliadiinia kohtaan. 
Erityisesti pienten lasten keliakiadiagnostiikassa voidaan käyttää vasta-ainemääritystä 
spesifille synteettiselle deamidoidulle gliadiinipeptidille. Osatyössä II osoitimme immu-
nofluorometriaan perustuvan (TR-IFMA) gliadiinipeptidivasta-aineita mittaavan testin 
olevan sekä hyvin sensitiivinen että spesifinen lasten keliakiadiagnostiikassa.
Osatyössä III vastasyntyneistä seulottiin HLA-DQB1*02 ja -DQA1*05 alleelien suhteen 
positiiviset lapset, joita seurattiin 3:een tai 4:ään ikävuoteen asti määrittämällä transg-
lutaminaasi- ja gliadiinipeptidivasta-aineita sekä perifeerisen veren gliadiinispesifisiä 
T-soluvasteita. Kumulatiivinen transglutaminaasivasta-ainepositiivisuus 4:ään ikävuo-
teen mennessä oli 6,5 % ja keliakian ilmaantuvuus 3,1 %. Yhtä lasta lukuun ottamatta 
kaikki keliakiaan sairastuneet lapset diagnosoitiin vasta-aineseurannan perusteella il-
man edeltävää kliinistä keliakiaepäilyä. Osoitimme sekä retrospektiivisesti (II) että pros-
pektiivisesti (III), että suurimmalla osalla keliakiaan sairastuneista lapsista erityisesti 
IgG luokan gliadiinipeptidivasta-aineet ilmaantuivat keskimäärin vuotta aiemmin kuin 
trans glutaminaasivasta-ainepositiivisuus. Prospektiivisessa seurannassa (III) perifeerisen 
veren gliadiinispesifiset T-soluvasteet olivat suhteellisen yleisiä 9 ja 12 kuukauden iässä, 
mutta positiivisten vasteiden määrä laski seurannan myötä samalle tasolle kuin hieman 
VIII
vanhemmilla kontrollilapsilla osatyössä I. Gliadiinispesifisten T-soluvasteiden yleisyys 
voi liittyä varhaiseen immunisaatioon gluteenille, joka suurimmalla osalla lapsista ei joh-
da keliakialle spesifisten vasta-aineiden ilmaantumiseen eikä kliinisen taudin puhkeami-
seen. 
Tämän tutkimuksen perusteella keliakian varhaisempi havaitseminen voisi olla mah-
dollista seuraamalla säännöllisesti transglutaminaasi- ja gliadiinipeptidivasta-aineita 
keliakialle geneettisesti alttiilla lapsilla. Sen sijaan perifeerisen veren gliadiinispesifisten 
T-soluvasteiden seurannalla ei ole vaikutusta keliakian varhaisempaan  toteamiseen. 
Osoitimme, että gliadiinipeptidivasta-aineet voivat olla ensimmäinen todettavissa oleva 
immunologinen merkkiaine suurella osalla keliakiaan sairastuneista lapsipotilaista.
Yleinen suomalainen asiasanasto: keliakia, immuunivaste, autovasta-aineet, gliadiinit, lymfosyytit
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1 Introduction
 
Celiac disease, first described in 1888 by Samuel Gee, has been historically characterized 
as severe diarrhoea associated with weight loss and growth disturbance in infancy caused 
by an intolerance to dietary gliadin, a subset of gluten proteins (1). Nowadays, the clas-
sical clinical presentation has become rare and celiac disease manifests currently with 
more mild gastrointestinal (GI) symptoms and is observed in all age groups (2-5). The 
most common extraintestinal manifestation of celiac disease is dermatitis herpetiformis, a 
blistering skin disease (6,7). Other extraintestinal manifestations, such as gluten-sensitive 
ataxia and mental disorders, have also been described (8,9). A lifelong gluten-free diet is 
currently the only essential treatment for all forms of celiac disease. 
Celiac disease has a strong HLA-associated genetic predisposition as approximately 
90% of celiac disease patients express the HLA-DQ2 molecule and the rest of the pa-
tients express the HLA-DQ8 molecule (10,11). Although the expression of the HLA-DQ2 
or -DQ8 molecules is necessary for the development of celiac disease, this alone is not suf-
ficient and environmental factors also play a central role in disease pathogenesis. Dietary 
gluten is the major environmental factor known to be necessary for the development of 
celiac disease. Several non-dietary environmental factors such as neonatal infections and 
the season of birth have been suggested to increase the risk for celiac disease but none of 
them have been confirmed yet (12,13).
Celiac disease is thought to be a T-cell mediated autoimmune disease, in which im-
munogenic gliadin peptides, after passing the mucosal layer in the intestinal mucosa, can 
activate the adaptive immune response. These gliadin peptides are presented to CD4+ 
T cells in the context of the HLA-DQ2 or -DQ8 molecules on antigen presenting cells 
(APCs). CD4+ T cells recognizing gliadin epitopes were first isolated from small intes-
tine biopsies of patients with celiac disease (10,11). T cells specific to deamidated gliadin 
have also been demonstrated in the circulation of adult patients with active disease, most 
commonly after oral gluten challenge (14-16). Gliadin-specific T-cell responses have been 
studied far less widely in children with celiac disease, but the small intestinal T-cell re-
sponse observed in young individuals appears to target a more diverse array of gliadin 
epitopes compared to that in adults (17,18). The appearance of peripheral blood CD4+ T 
cells specific to gliadin is a non-invasive tool for detecting the immune response and may 
allow the earlier detection of the disease process.
Serological screening has a central role in the diagnosis of celiac disease. Antibody re-
sponses to gluten components and to self-tissue structures have been characterized and 
used in the diagnosis of celiac disease ever since anti-gliadin antibodies (AGA) were first 
described in 1958 (19,20). Nowadays, AGA assays are no more recommended for celiac 
disease diagnostics, as their specificity is relatively poor (21). The antireticulin antibod-
ies (ARA), against the reticular fibers of endomysium were discovered in 1977 and used 
widely in the diagnosis of celiac disease (22-24). The ARA assay is also no longer recom-
mended, as nowadays more sensitive and specific tests have been developed (21,25,26). 
Endomysial antibodies (EmA), in turn, were discovered in 1983. They perform with high 
specificity in the diagnosis of celiac disease, but the method is laborious and the interpre-
tation of its results somewhat subjective (27). In 1997, tissue transglutaminase (tTG) was 
discovered to be the autoantigen targeted by EmA (28) and since then, the screening of 
celiac disease has been based on the measurement of immunoglobulin (Ig) class A tissue 
transglutaminase autoantibody (tTGA) (21). Assays detecting IgA and IgG antibodies to 
deamidated gliadin peptides (anti-DGP) have been developed most recently and it has 
been demonstrated that they may appear as a first marker of the celiac disease (29,30). 
The diagnosis of suspected celiac disease is currently confirmed by the typical histolog-
2ical changes in the small intestine, crypt hyperplasia and villous atrophy with increased 
number of intraepithelial lymphocytes (IELs), detected by duodenal biopsy (31). Howev-
er, recently proposed new criteria by The European Society for Paediatric Gastroenterolo-
gy, Hepatology and Nutrition (ESPGHAN) has underlined the significance of serological 
testing in the diagnosis of celiac disease in children and the need for duodenal biopsy is 
being evaluated critically (21). 
The aim of the present study was 1) to analyze the development of gliadin-specific im-
mune responses in children who are genetically at high risk for the development of celiac 
disease and 2) to evaluate whether these responses can be detected before the clinical on-
set of the disease. To this end, serum tTGA and anti-DGP antibodies as well as peripheral 
blood gliadin-specific T-cell responses were assessed. 
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2.1 CLINICAL FEATURES OF CELIAC DISEASE
2�1�1 Classical gastrointestinal celiac disease
Celiac disease is a chronic small intestinal immune-mediated enteropathy caused by di-
etary gluten in genetically predisposed individuals. Celiac disease was historically char-
acterized as severe diarrhoea associated with growth disturbance in infancy (2). This 
classical presentation of celiac disease has become rare and nowadays the disease often 
manifests with milder GI symptoms, such as chronic diarrhoea, abdominal pain and dis-
tension both in adults and in children (3,32-34). Moreover, in pediatric patients the pro-
portion of individuals with minor or atypical symptoms has increased (35,36). Undiag-
nosed celiac disease may also cause malabsorption and deficiencies of nutrients leading 
to various chronic symptoms such as general fatigue, anemia and osteoporosis. 
2�1�2 Extraintestinal manifestations and complications
Dermatitis herpetiformis, a blistering skin disease, has been considered as a variant form 
of celiac disease with the same genetic background (6,7,37). Although only a minority of 
these patients have GI symptoms, up to 60–80% of them have pathological changes in 
the intestinal mucosa (38,39). The diagnosis of dermatitis herpetiformis is based on the 
demonstration of granular IgA deposits in the papillary dermis by a direct immunoflu-
orescence method (7,40). A gluten-free diet is also the essential treatment in dermatitis 
herpetiformis (41,42). Dermatitis herpetiformis rarely affects children.
Several neurological symptoms associated with the appearance of celiac disease anti-
bodies have also been described (43). It has been suggested that tissue transglutaminase 
autoantibodies, specifically, may play a central pathogenic role in the extraintestinal man-
ifestations associated with celiac disease (8,44). The most common neurological manifes-
tation of gluten sensitivity is ataxia (8,45). Other neurological symptoms such as polyneu-
ropathy and early-onset dementia have also been described (46,47). Undiagnosed celiac 
disease has been shown to be associated with mental and behavioural disorders, such as 
depression during adolescence (9). Several reproductive problems, such as infertility and 
increased risk of miscarriage, have also been associated with celiac disease (48). In addi-
tion to these, other non-classical symptoms, such as dental enamel defects, aphthous ul-
cer, arthritis and abnormalities in liver function tests, and even severe liver disease, have 
been demonstrated (49-53). It has also been suggested that calcium malabsorption due to 
celiac disease may lead to decreased bone mineral density and increased fracture risk but 
these results are currently conflicting (54-57).
The association of celiac disease with cancer was established in the 1930s. An increased 
risk for lymphomas and GI cancers has been reported in several studies, albeit with great 
variation. Early studies reported a 50- to 100-fold risk for such malignancies but subse-
quent later studies have estimated the risk to be 3- to 6-fold higher (58-60). The increased 
risk for lymphomas and GI cancers is strongly related to refractory celiac disease, which 
manifests as persistent or recurrent malabsorptive symptoms and villous atrophy despite 
of strict adherence to a gluten-free diet (61). The overall risk for lymphomas and GI can-
cers in patients following a strict gluten-free diet is increased only early after diagnosis 
and later on it decreases to a more moderate level (62,63). In all, due to improved diag-
nostics, the risk of complications of celiac disease has decreased in recent times. However, 
there are still undiagnosed patients who are at risk of long-term complications (64). 
42�1�3 Prevalence of screening-detected celiac disease
The prevalence of screening-detected celiac disease has been reported to be as high as 10–20% 
in studies of subjects with a family history of the disease (65-68). Moreover, screening done in 
patients with related autoimmune diseases, in particular type 1 diabetes (T1D), has revealed 
that there is a large number of cases of silent celiac disease (69-73). The co-morbidity with 
T1D has been partially explained with the same predisposing genetic background for these 
diseases but the actual mechanism still remains unresolved. Celiac disease has been shown to 
be overrepresented not only among patients with autoimmune disorders but also in patients 
with some chromosomal disorders, such as Down’s syndrome (74-78). The frequency of celi-
ac disease is also remarkably higher among patients with selective IgA deficiency than in the 
general population, but this may also be related to the associations of both diseases with the 
same HLA haplotype (79-81). 
2.2 EPIDEMIOLOGY OF CELIAC DISEASE
Both the prevalence and the risk of celiac disease show extensive geographical variation 
(82-87). The prevalence of celiac disease in the general population in Western Europe 
and in North America is around 1% (88-92). According to population-based studies it 
seems that there are still some countries, such as Japan, China and some African coun-
tries, where celiac disease is almost non-existent and only a few cases have been described 
(92,93). Screening studies done in Finland have demonstrated a 1% prevalence of celiac 
disease in children and even a 2% prevalence in adults (35,94). Moreover, the prevalence 
of celiac disease has increased both in Finland and in North America over the last decades 
(89,94,95). Interestingly, a similar trend has been reported in the prevalence of allergic 
diseases and T1D (94,96-99). 
While the prevalence of celiac disease has increased over the last decades, the reasons 
for this are still under investigation (89,95). In addition to the improved diagnostics also 
the true prevalence of celiac disease has increased. Environmental factors, such as the 
so-called hygiene hypothesis, have been suggested to be one explanation, similar to what 
has previously been suggested for the increase in allergy and atopy (70,100,101). A strong 
increase in the incidence of celiac disease was discovered in Sweden in the 1980s, and 
this offered a great opportunity to analyze the possible environmental factors involved 
(102,103). Based on these epidemiological studies, changes in infant feeding recommen-
dations have been suggested to be one key explanation for the increased prevalence of 
celiac disease (see 2.3.2.1).
Screening studies in children have shown that the risk for celiac disease has increased 
more in girls compared to boys (104-106). However, conflicting results on this issue have 
been reported in one Swedish study, in which the prevalence of screening-detected ce-
liac disease was equal in girls and boys (107). The prevalence of celiac disease in adult 
patients has been shown to be three-fold higher in women compared to men (108). It is 
well known that autoimmune diseases are generally more common in women (109), with 
a protective effect of androgens hypothesized as an explanation (109,110). However, the 
higher frequency of celiac disease in prepubertal girls suggests that the higher frequency 
of celiac disease cannot solely be explained by the sex-hormone theory. 
52.3. PATHOGENESIS OF CELIAC DISEASE
2�3�1 Genetics of celiac disease
2�3�1�1 HLA genes
The heredity of celiac disease was first suggested in 1951 (111) by the higher prevalence 
of celiac disease in family members of celiac disease patients. The prevalence in first-de-
gree relatives is around 20% (65,66,112,113). Importantly, the prevalence of celiac disease 
in monozygotic twins has been reported to be around 70–80% (66,114), which is much 
higher than the prevalence of the disease in heterozygous twins. This specifically demon-
strates that genetic factors have a central role in the pathogenesis of celiac disease.
Celiac disease is known to have one of the strongest human leucocyte antigen (HLA) 
associations of all autoimmune diseases. The HLA-associated genetic risk comprises 
around 30–50% of the entire genetic risk for the development of celiac disease (115-119). 
HLA-genes, which encode the HLA class I and class II molecules, are located on chro-
mosome 6p22 (120,121). HLA class I and II molecules are membrane proteins, both of 
which have extracellular domains that form a cleft in which a peptide fragment is bound. 
However, they differ slightly in their structures, as the outer domains of HLA class I mol-
ecules are formed by α-1 and α-2 chains whereas HLA class II molecules are heterodimers 
formed by α- and β-chains. HLA class I molecules are expressed in most of human cells 
whereas HLA class II molecules are expressed predominantly in APCs. 
Association of alleles in the HLA complex with celiac disease was first described in 
1972 using serological methods (122). HLA-association with celiac disease was first re-
ported with the HLA class I B8 and HLA class II DR3 alleles (123,124) A more specific 
HLA-association was established in 1989 when Sollid and co-workers found an associa-
tion between celiac disease and the combination of alleles encoding the α-chain DQA1*05 
and the β-chain DQB1*02 of the HLA class II DQ2 heterodimer (125). 
More than 90% of celiac disease patients express one or two copies of HLA-DQ2 encoded 
by alleles DQA1*05 and DQB1*02 (10,126). In patients with the HLA-DR3-DQ2 haplotype 
DQA1*05 and DQB1*02 alleles are located on the same chromosome in the so-called cis-po-
sition, whereas in patients carrying both the HLA-DR7-DQ2 an HLA-DR5-DQ7 haplotypes 
the alleles are located on the opposite chromosomes in the so-called trans-position (Figure 
1.) (125,126). The highest risk for celiac disease has been reported in DR3-DQ2 homozygous 
and DR3-DQ2 and DR7-DQ2 heterozygous individuals, which may be explained by a gene 
dose effect of the DQB1*02 allele (87,127,128). The HLA-DQ2 molecule may also be encod-
ed by the alleles DQA1*0201 and DQB1*0202. The expression of this molecule is associated 
with lower risk of celiac disease than HLA-DQ2 encoded by DQA1*05, possibly due to the 
replacement of a tyrosine by phenylalanine residue in DQα at position 22, which has been 
described to be important for the peptide binding of gluten epitopes in the context of HLA-
DQ2 (129,130). The remaining 10% of celiac disease patients, who do not express HLA-DQ2, 
express the HLA-DQ8 molecule, encoded by the DQA1*03 and DQB1*0302 alleles. The risk 
for celiac disease in these patients, however, is considerably lower than in those expressing 
HLA-DQ2 (11,126,129,131). In very rare cases, subjects with celiac disease carry either the 
DQA1*0501 or DQB1*02 allele alone (132).
Individuals who carry HLA-DR3-DQ2 and/or HLA-DR4-DQ8 are also predisposed to 
T1D and, therefore, the link between celiac disease and T1D is remarkably strong. Ap-
proximately 5–20% of patients with type T1D develop celiac disease during their life-
times. Celiac disease is also associated with an increased risk for other autoimmune dis-
eases; approximately 15–20% of patients with celiac disease are already affected by other 
autoimmune diseases or will develop those at a later stage in life (133,134).
62�3�1�2 Non-HLA genes
The prevalence of HLA-DQ2 or -DQ8 expression is around 20–30% in the general popula-
tion but approximately only around 3% of these individuals develop celiac disease during 
their lifetimes (135). Therefore, other genetic and environmental factors clearly also play a 
role. A number of non-HLA gene regions have been shown to be associated to celiac disease 
in multiple genome wide association studies but it has been estimated that all the non-HLA 
risk genes together explain only approximately 5% of the entire risk (116-119,136). The ma-
jority of the non-HLA genes identified in these studies are immune-related genes and many 
of them are associated with T and B cell function (137). The genomic region containing the 
CTLA-4 gene on chromosome 2q33 has been reported to associate with autoimmunity in 
general, and the CTLA-4 polymorphism is one of the most studied non-HLA gene associ-
ation also in celiac disease (138,139). Although several studies have reported a linkage be-
tween polymorphisms in the CTLA-4 gene and celiac disease, conflicting results have also 
been reported (140-144). In addition to the CTLA-4 locus, the involvement of several other 
gene loci has also been studied. Chromosomes 5 and 19 are of major interest: both the 5q31-
33 and 19p.13.1 genetic regions have been reported to have a linkage to celiac disease (145-
151). There are also some promising results for an association with chromosome 9p21-p31 
(148,149,151). Many of the identified non-HLA celiac disease risk loci are also associated 
with other immune-related diseases, in particular T1D and rheumatoid arthritis (152-154). 
The similar genetic background among these autoimmune diseases indicates that parts of 
their pathogenic pathways are common. In all, it seems that none of the non-HLA genes 
identified to date have a central role in the genetic risk by themselves but their combined 
genetic effect has been suggested to have a significant impact.
2�3�2 Environmental factors 
2�3�2�1 Dietary gluten and gluten introduction
Dietary gluten is the major environmental factor affecting celiac disease. Gluten is a pro-
tein found in wheat, barley and rye, that is rich in proline and glutamine residues (155). 
Wheat gluten contains two main fractions: soluble gliadin storage proteins and insoluble 
glutenin proteins (Figure 2.) (155). Although gliadin originally refers to the soluble pro-
line fraction of wheat, the name is commonly also used for the similar fractions, hordein 
and secalin, in barley and rye, respectively. Gliadins are monomers and classified accord-
ing to their different primary structures into the α, γ- and ω-type gliadins, whereas glute-
nins are polymers with high or low molecular weight (155). Oat has been deemed safe in 
the diet of most celiac disease patients probably since instead of gluten it contains avenin, 
a protein with a different prolamin structure (156).
Figure 1. The HLA-DQ2 (DQA1*05–DQB1*02) heterodimer is encoded in cis position in indi-
viduals with the DR3–DQ2 haplotype an in trans position in individuals heterozygous for the 
DR5–DQ7 and DR7–DQ2 haplotypes. The HLA-DQ8 (DQA1*03–DQB1*0302) heterodimer is 
encoded in cis position in individuals with the DR4-DQ8 haplotype.
DR7-DQ2
DR5-DQ7
DQB1 DQA1
Heterodimer HLA-DQ2 
encoded in trans-position
*0505
*0202
DR3-DQ2
DQB1 DQA1
Heterodimer HLA-DQ2 
encoded in cis-position
*0201 *0501 DR4-DQ8
DQA1DQB1
Heterodimer HLA-DQ8
encoded in cis-position
*0302 *03
7Wheat gluten was identified as a trigger of celiac disease already in the early 1950s by Dicke 
et al. (157). The age at which gluten was introduced was suggested to play a central role in 
the development of celiac disease much later, in the late 1980s (158,159). Since then, both 
the timing of gluten introduction and breastfeeding has been suspected to be associated 
with the increased risk for development of celiac disease in several studies (160-163). Mul-
tiple studies have tried to determine whether breastfeeding itself affects the risk for celiac 
disease and whether the duration of breastfeeding decreases the risk of celiac disease. Most 
of these studies have been based on retrospective analysis and thus lack a proper case-con-
trol setting. The largest case-control study so far was performed in Sweden by Peters and 
co-workers (164). They reported that on-going breastfeeding during gluten introduction at 
infancy has a protective effect on future celiac disease in children under 2 years of age but 
not in older children between 2 and 15 years (Peters et al. 2001). Although the protective 
effect of breastfeeding for celiac disease risk has been reported widely in epidemiological 
studies, this effect has not been found in all studies (103,160,161,165,166). Decker et al. 
have reported that prolonged breastfeeding was in fact associated with an increased risk 
for celiac disease (166). Moreover, the actual mechanism of the possible protective effect 
of breastfeeding remains unsolved. One hypothesis is that continued breastfeeding could 
reduce the amount of gluten introduced to the infant’s diet (165). It has also been suggested 
that human milk IgA antibodies could decrease the immune response against gluten in the 
gut of infants (163). 
Since early gluten introduction has also been suggested as a trigger for celiac disease, 
several studies have examined the optimal age for gluten introduction (158,159). The ef-
fect of the timing of gluten introduction was suspected in Sweden between 1984 and 1996, 
when there was a strong increase in the incidence of celiac disease, which was related to 
new national nutritional recommendations that suggested postponing gluten introduction 
from 4 to 6 months of age (167,168). The incidence was also reduced when these recom-
mendations were changed in 1996. The new national recommendations of infant feeding in 
Sweden suggest introducing gluten in small amounts between the age of 4 and 6 months 
while the child is still breastfed (167,169). Norris et al. have also shown an association be-
tween the age at which gluten is introduced and the risk of celiac disease (161). Based on 
several studies, gluten introduction before the age of 4 months or after 6 months without 
concurrent breastfeeding has been suggested to increase the risk for development of celiac 
disease (103,160,161,167,168,170). However, there has been a debate whether later gluten 
introduction only delays the onset of celiac disease in predisposed individuals instead of 
actually reducing the risk of the disease. In a recent Norwegian nationwide prospective 
study it was observed that a higher risk of celiac disease was associated with delayed glu-
ten introduction after 6 months of age, as well as with prolonged breastfeeding over 12 
months (171). 
Figure 2. Classification of wheat gluten proteins.
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8Most importantly, recently published large prospective studies have not provided sup-
port for the role of breastfeeding or age of gluten introduction for celiac disease risk. In 
these studies, neither the duration of breastfeeding, age at gluten introduction, nor simul-
taneous ongoing breastfeeding during gluten introduction have affected the probability 
of celiac disease (106,172,173). 
2�3�2�2 Other environmental factors
Several non-dietary environmental factors have been suggested to be risk factors for ce-
liac disease. These factors include both intrauterine and perinatal conditions (174). Sand-
berg-Bennich et al. have reported that both neonatal infections and small size for ges-
tational age increase the risk of celiac disease (175). Multiple studies have shown that 
maternal smoking associates with a lower risk of celiac disease (175-177), and that the 
season of birth associates with an increased risk of celiac disease (12,13,178). Two large 
studies have suggested that children born in spring or summer have an increased risk for 
celiac disease (13,179). This has been explained by the timing of dietary gluten introduc-
tion during the wintertime when these children are simultaneously affected by seasonal 
infectious diseases.
The etiological role of viral infections is one the major area of research in all autoim-
mune diseases. Ever since Kagnoff and co-workers suggested a possible role for adeno-
virus in the pathogenesis of celiac disease, several studies have tried to evaluate whether 
infectious diseases associate with celiac disease (180). So far, only a few of the studies 
have managed to find any evidence for an association. Similar findings of a potential role 
of virus infections in T1D has raised the interest of studying this aspect in celiac disease 
as well, since T1D also confers an increased risk for celiac disease (181-184). Rotavirus 
infections have been shown to associate with an increased risk for celiac disease in a US 
population (12). In a German study, it was found that children with celiac disease had 
more often earlier gastrointestinal infections prior to celiac disease diagnosis (166). In 
contrast to these reports, one prospective study by Welander et al. reported that infection 
or gastroenteritis at the age of gluten introduction did not associate with the risk of future 
celiac disease (185).
Several new environmental hypotheses on the etiology of celiac disease have also re-
cently been presented. The finding of an increased risk of celiac disease associated with 
caesarean section has been explained by the protection provided by the vaginal bacte-
rial flora colonizing the infant during normal delivery (166), although this has not been 
demonstrated in all studies (176,186,187). Gut microbiota is an interesting novel point of 
view in explaining the pathogenesis of all autoimmune diseases. In recent years, the role of 
the gut microbiota has been studied also in celiac disease. Several studies have shown that 
the different composition of intestinal bacterial populations, such as increased gram-nega-
tive bacteria and decreased bifidobacteria, is associated with celiac disease but the specific 
role of microbes in the pathogenesis of celiac disease is still unresolved (188-190).
2�3�3 Immunopathogenesis of celiac disease
2�3�3�1 T cell development and function
It is still open for debate, why dietary gluten causes an inflammatory process in the small 
intestine and leads to the destruction of epithelia in some individuals. Celiac disease 
has been classified as a T-cell mediated autoimmune type disease. T cells, or T lympho-
cytes, are characterized by their expression of T cell receptors (TCR) composed of α- and 
β-chains (αβ-TCR) and are further categorized into helper T cells (CD4+ T cells) and cy-
9totoxic T cells (CD8+ T cells) by their phenotypic and functional characteristics (191,192). 
T cells originate from bone marrow stem cells and their maturation process occurs in 
the thymus. The progenitor T cells that enter the perimedullary cortex of the thymus are 
CD4/CD8 double-negative (CD4-CD8-) and as they migrate to the outer region of the thy-
mic cortex, the expression of both CD4 and CD8 molecules on the cell surface is induced 
(193). Further, as CD4+CD8+ T cells migrate back to the medulla, they undergo positive 
selection, in which those T cells that do not recognize self-peptides in the context of self 
HLA-molecules die by apoptosis (194). Only a minority of the CD4+CD8+ T cells, approx-
imately 10%, survives this process. If the T cell recognizes a self-peptide in the context 
of an HLA class I molecule, CD4 expression is downregulated and the cell becomes sin-
gle-positive for CD8 expression. Analogously, if the self-peptide is recognized in the con-
text of an HLA class II molecule, CD8 expression is downregulated and the cell becomes 
single-positive for CD4 expression (193). Subsequently, these single positive CD4+ and 
CD8+ T cells undergo negative selection in which T cells that recognize a self-peptide too 
strongly are induced to undergo apoptosis in order to purge the mature T cell repertoire 
of autoreactive T cells (194). Finally, mature CD4+ and CD8+ T cells are released into the 
circulation.
Several other subsets of T cells have also been described. The other form of the TCR is 
composed of γ/δ chains and T cells expressing these types of TCR are called γ/δ T cells. 
Some of γ/δ T cells express the CD8 molecule but most of them are negative for both 
CD4 and CD8 molecules (195). The γ/δ T cells are present mostly in the gut epithelium. 
Another central group of T cells is the natural killer (NK) T cells, which may express both 
αβ-TCR and receptors that are characteristic for NK cells (196).
Despite effective central tolerance, a minor population of autoreactive T cells can avoid 
it and enter the circulation. The possible activation of these autoreactive T cells in the pe-
riphery is suppressed by several mechanisms of peripheral tolerance, including ignorance, 
deletion, anergy and active regulation (197,198). Of these mechanisms, active regulation 
by so-called regulatory T cells (Treg) appears to be the most important one (197). The two 
main subtypes of Tregs identified are T cells expressing the forkhead box P3 transcription 
factor (FOXP3+ Tregs) and the T regulatory type 1 (Tr1) cells (197). Tregs are able to sup-
press the activation and proliferation of effector T cells using several mechanisms, one of 
which is the inhibition of T cell co-stimulation via cytotoxic T lymphocyte associated pro-
tein 4 (CTLA-4), which is expressed on the cell surface of Tregs (199,200). In patients with 
active celiac disease, effector T cells appear to be resistant to suppression by Tregs, which 
may contribute to the loss of tolerance to gluten and also to self-antigens (201).
After encountering their cognate antigen naïve CD4+ T cells (see 2.3.3.2) become acti-
vated and they begin to proliferate and differentiate into effector T cells. After the expo-
sure to the antigen has ended most of the effector T cells die by apoptosis and only some 
of the effector T cells return to a resting state and survive as long-living memory T cells 
(202,203). Naïve and memory T cells in humans have been characterized by their mutu-
ally exclusive expression of CD45RA and CD45RO molecules, respectively. In vitro stud-
ies demonstrate that upon T-cell activation and proliferation naïve T cells first acquire 
the expression of CD45RO and subsequently lose the expression of CD45RA (204). CD4+ 
effector T cells have been classified into further subsets based on their cytokine profile. 
The first two subsets, Th1 and Th2 cells were first described in the 1980s (205). Th1 cells 
produce mainly interleukin (IL)-2, interferon gamma (IFN-γ) and tumour necrosis factor 
alpha (TNF-α) whereas Th2 cells produce IL-4, IL-5, IL-6 and IL-13 (206). Although Th 
cells have their dominant cytokine profile individual T cells may produce heterogeneous 
patterns of cytokines, such as IL-10 and TGF-β, which have not been shown to be charac-
teristics for either Th1 or Th2 subset. Such T cells producing various mixtures of cytokines 
have been called Th0 cells (206). The characteristic functions of the two subsets of T cells 
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(Th1 and Th2) are executed via their dominant cytokines. The main functions of Th1 cells 
are the elimination of intracellular pathogens and the activation of inflammation and tis-
sue injury (206). Th2 cells, in turn, have a central role in mediating allergy and chronic 
inflammation and in the protection against helminthic and other parasite infections (206). 
A subset of T cells, called Th17 cells, has been characterized more recently (207). These 
Th17 cells produce IL-17 and are involved in the protection against extracellular microbes 
and fungi. Additional T cell subgroups, such as Th9 and Th22, have also been described 
(208,209). 
2�3�3�2 Innate and adaptive immune response in the pathogenesis of celiac disease
Celiac disease has been classified as a T-cell mediated autoimmune disease in which di-
etary gliadin causes the activation of both the innate and adaptive immune systems, which 
gives rise to disease pathogenesis (126,210). The gliadin protein is rich in proline amino 
acid residues and resistant to degradation by intestinal protease enzymes. Therefore, only 
Figure 3. Innate and adaptive immune response mechanisms involved in the pathogenesis of 
celiac disease. Incompletely digested gluten peptides pass the intestinal epithelium and are de-
amidated by tissue transglutaminase (tTG). The deamidated peptides are presented to CD4+ 
T cells by APCs in the context of the HLA-DQ2 or DQ8 molecule in the lamina propria. The acti-
vated CD4+ T cells differentiate into Th1 cells that produce proinflammatory cytokines such as 
IFN-γ and TNF-α. These cytokines, in turn, activate fibroblasts and inflammatory cells of the 
intestinal epithelium to produce the matrix metalloproteinase (MMP) responsible for matrix 
degradation, leading to the destruction of the small intestinal mucosa. Differentiated Th2 cells 
activate B cells to produce antibodies against gliadin and tissue transglutaminase. The toxic 
gliadin peptide (p31-43) can directly activate intraepithelial lymphocytes (IELs) of the innate 
immune system via IL-15. 
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Figure 4. The TCR, expressed on the CD4+ T cell, recognizes the deamidated gliadin peptide in 
the context of HLA-DQ2 or -DQ8 molecule, expressed on the surface of an APC. The co-stim-
ulatory signal is mediated by the binding of the CD28 receptor, present on the T cells, to the 
B7 co-stimulatory molecules, CD80 or CD86, expressed on activated APCs.
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a part of the dietary gliadin is degraded before it enters the intestinal mucosa (18,131). 
The harmful link between gluten exposure and developing the destruction of intestinal 
mucosa, as a sign of celiac disease, is the ability of gluten peptides to increase mucosal 
permeability to macromolecules. This increased intestinal permeability upon gluten ex-
posure occurs in all individuals. However, the mechanism that leads to mucosal damage 
only in some individuals is still under investigation (211). Zonulin is a eukaryotic protein 
that modulates tight junctions between cells (212,213). It has been demonstrated that glu-
ten peptides increase zonulin release from enterocytes, which in turn increases the per-
meability of intestinal mucosa and this phenomenon is enhanced in active celiac disease 
(213). Since all individuals release zonulin after gluten-exposure, other factors, such as 
the cytokine profile of intestinal lymphocytes may explain the enhanced permeability in 
patients with active celiac disease. This question, however still remains unresolved (211). 
Increased zonulin upregulation leads to reorganization of the cytoskeleton, tight junction 
opening and increased paracellular passage of antigenic macromolecules into the lamina 
propria (212,214). Finally, gliadin peptides pass the epithelium, possibly with the help of 
dendritic cells, by using a transcellular pathway (215). The process of innate and adaptive 
immune response is described in Figure 3.
 After gliadin peptides have passed the epithelium and entered into the mucosal layer 
they are able to activate an adaptive immune response by CD4+ T cells. Gluten protein 
itself contains only few negatively charged residues critical for efficient binding to HLA 
class II molecules. However, the deamidation by tissue transglutaminase present just be-
low the small intestinal epithelium, converts selected glutamine residues to negatively 
charged glutamic acids and thereby increases the binding affinity of the gluten peptides 
to certain class II molecules, namely HLA-DQ2 and -DQ8 (216-218). After deamidation, 
multiple peptides derived from several gluten proteins, α-, γ- and ω- gliadins, are bound 
strongly by HLA-DQ2 or -DQ8 molecules and expressed on the cell surface of APCs, such 
as dendritic cells, macrophages and B cells. These deamidated gluten peptide-HLA-DQ2/
DQ8 complexes finally activate the antigen-specific CD4+ T cells (218). The activation of 
CD4+ T cells requires two signals: a TCR-mediated signal and a co-stimulatory signal. 
TCR-mediated activation occurs when the TCR recognizes the peptide in the context of an 
HLA-DQ2 or-DQ8 molecule. The co-stimulatory signal is mediated by the binding of the 
CD28 receptor expressed on the naïve T cells to the B7 co-stimulatory molecules, CD80 or 
CD86, expressed on activated APCs (219,220). The antigen-specific CD4+ T-cell activation 
caused by deamidated gliadin peptides, described in Figure 4, is the key reaction in the 
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pathogenic mechanism of celiac disease, since the majority of the gliadin-specific intes-
tinal T cells from celiac disease patients recognize gliadin proteins only after they have 
undergone deamidation (10,11,216).
 Activation of CD4+ T cells leads to their differentiation along both Th1 and Th2 polar-
ized pathways. Th1-polarized cells begin to produce IFN-γ and other proinflammatory 
cytokines, which leads to the destruction of epithelial cells (see 2.3.3.3) (126,221). Th2-po-
larized cells, in turn, promote the differentation of B cells into plasma cells capable of 
producing antibodies not only to gliadin but also to tTG.
T cells specific to tissue transglutaminase have only been demonstrated in the periph-
eral blood of celiac disease patients but not in the intestinal mucosa whereas B cells spe-
cific to tTG are readily detectable there (222-224). It has been suggested that when gliadin 
and tTG are physically linked during the deamidation reaction, tTG-specific autoreactive 
B cells can endocytose and process both of these antigens and present peptides derived 
from gliadin on their HLA class II molecules. Gliadin-specific CD4+ helper T cells that ex-
ist in the intestinal mucosa then provide help for these tTG-specific B cells leading to the 
production of antibodies to tTG but how this happens is still under investigation (222). 
When gliadin is withdrawn from the diet, T-cell help for anti-tTG specific B cells ceases 
and consequently the titers of antibodies to tTG decline in patients with celiac disease 
(222). Recent studies have demonstrated that the antibody response to tTG in celiac dis-
ease is dynamically regulated in response to dietary gluten with low-degree maintenance 
of both autoreactive plasma cells and memory B cells in patients in remission (225,226).
Although the antibody response and the detection of antibodies to tissue transgluta-
minase is a hallmark of disease development, it is still unclear whether tTGA themselves 
have a role in the pathogenesis that leads to the destruction of the intestinal mucosa. tTG 
is expressed at the epithelial border and extracellularly in the subepithelial region and it 
has been demonstrated that the level of its expression is increased in active celiac disease 
(216,227). In a study by Kiraly et al. it was shown that tTGA may have an inhibitory ef-
fect on tTG whereas Myrsky et al. have demonstrated that these antibodies increase the 
activity of tTG (228,229). Interestingly, deposits of IgA class tTGA can be found in the in-
testinal mucosa even before villous atrophy and tTGA seropositivity occur (230,231). This 
phenomenon could potentially be used for earlier detection of celiac disease.
2�3�3�3 Progression to a destructive immune response
As described above, the activation of Th1-type CD4+ T cells in response to gluten peptides 
leads to the production of proinflammatory cytokines, mainly IFN-γ and TNF-α, which 
promotes severe inflammation (232,233). In line with this, IFN-γ has been shown to be the 
dominant proinflammatory cytokine observed in the gut mucosa of gliadin-challenged 
celiac disease patients (232,234). In addition to CD4+ T cells, IFN-γ is also produced by 
CD8+ T cells in both the epithelium and the lamina propria (235,236). Overall, Th1-type 
cytokines activate tissue resident stromal and immune cells in the intestinal epithelium 
to produce matrix metalloproteases (MMP), which leads to mucosal damage (237). Glia-
din-specific T cells in the gut mucosa also produce high levels of IL-21, which amplifies 
the Th1-polarized response and enhances the secretion of extracellular matrix-degrading 
proteases by stromal cells and chemoattractants by epithelial cells (238-242). More recent-
ly, it has been suggested that Th17 cells, which produce IL-17A, may also be involved in 
the pathogenesis of celiac disease of the intestinal mucosa, but the results supporting this 
hypothesis are still conflicting (233,239,243). 
CD8+ T cells also have a central role in the pathogenesis of celiac disease and their ap-
pearance in the epithelia is one of the diagnostic markers of celiac disease. CD8+ T cells 
can recognize gliadin peptides that are 8–12 amino acids long, such as p123-132 derived 
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from α-gliadin, in the context of HLA-I molecules expressed on the epithelial cells (244-
247). Studies have also demonstrated that gliadin activates mucosal CD8+ T cells and 
support the hypothesis that IELs can present gliadin-derived peptides to both CD4+ and 
CD8+ T cells.
The destruction of the intestinal mucosa is also mediated by the innate immune re-
sponse. In addition to deamidated peptides, toxic gliadin peptides, mainly α-gliadin-de-
rived p31-43, can activate the innate immune response to produce IL-15, independently 
of the adaptive immune response (246-248). IL-15 is a proinflammatory cytokine that is 
mainly produced by monocytes, macrophages, dendritic cells and epithelial cells. The 
toxic p31-43 peptide has been shown to induce the production of IL-15 in both the epithe-
lium and lamina propria in patients with active celiac disease and to further increase the 
migration of IELs and their activation to killer cells (245,249). Furthermore, this toxic pep-
tide has been shown to induce increased expression of the MICA molecule in enterocytes 
and NKG2D receptor in NK cells, α/β and γ/δ cells and cytotoxic CD8+ T cells (245,249). 
Activated IELs drive the cells expressing MICA into apoptosis causing further damage to 
the intestinal mucosa (246). Taken together, IL-15 production by innate immune cells is a 
hallmark of celiac disease and the most crucial effector mechanism of the innate immune 
response is the MICA/NKG2D-mediated cytolysis of epithelial cells (246,250).
2�3�3�4 Gliadin epitopes recognized by CD4+ T cells
Gliadin-specific CD4+ T cells were first identified through the analyses of intestinal T 
cells. Lundin et al. demonstrated that intestinal CD4+ T cells from patients with celiac 
disease patients recognize gliadin peptides from gluten but not from proteins of other 
cereals, after in vitro stimulation (10). Since the examination of intestinal gliadin-specific 
T cells requires isolation of the cells from active celiac disease lesions obtained by intes-
tinal biopsy, this approach is somewhat laborious to perform. Therefore, many of the 
more recent studies have been performed with peripheral blood, where gliadin-specific 
T cells are also expected to be present after their initial antigen-driven expansion in the 
intestine and subsequent recirculation via systemic circulation. Several studies have con-
firmed that CD4+ T cells specific to deamidated gliadin epitopes can be detected in the 
peripheral blood in the majority of patients with active celiac disease. However, the fre-
quency of these gliadin-specific CD4+ T cells in the circulation is relatively low and thus 
in most of the studies patients have been challenged to oral gluten to enhance the number 
of antigen-specific T cells (14-16,251). A Norwegian study group has recently shown that 
gliadin-specific CD4+ T cells are detectable in the circulation also without oral gluten 
challenge by using a sensitive HLA class tetramer method to visualize these cells (252). 
Deamidation of gliadin by tTG leads to the conversion of glutamine residues to negative-
ly charged glutamic acid residues. This in turn facilitates the binding of gliadin peptides 
to the disease-associated HLA-DQ2 and -DQ8 molecules that prefer negatively charged 
amino acids in their binding pockets (126,216,218). Several studies have demonstrated that 
CD4+ T cell responses to deamidated gliadin are readily detected in peripheral blood after 
gluten challenge whereas no responses are seen in celiac disease patients on a gluten-free 
diet (14-16). It has also been established that CD4+ T cell reactivity to gluten increases after 
deamidation in patients with active celiac disease but not in healthy controls (15,16,253). 
Ben-Horin et al. reported that CD4+ memory T cell responses to deamidated gliadin were 
detected using a CFSE-based in vitro proliferation assay in approximately half of the stud-
ied adult celiac disease patients on a gluten-free diet. Interestingly, however, about half of 
the patients did not show any reactivity to deamidated gliadin (254). 
Two deamidated immunodominant epitopes of α-gliadin have been identified, which 
are predominantly recognized by both intestinal and peripheral blood gliadin-specific 
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CD4+ T cells from nearly all adult patients with celiac disease (14,16,17). Gliadin peptides 
QLQPFPQPELPY (Q12Y) and PQPELPYPQPELPY (P14Y) have been demonstrated to 
contain the immunodominant epitopes α-I (amino acids 57–68) and α-II (62–75), respec-
tively (17). However, Vader et al. have investigated the epitope-specificity of gliadin-spe-
cific CD4+ T cells isolated from the small intestine of children with celiac disease and 
demonstrated that T-cell responses in children appear to be more variable than in adults. 
T-cell responses in children are directed against multiple gliadin and gluten peptides and 
also toward native gluten peptides instead of the earlier described immunodominant epi-
topes of α-gliadin (18). Moreover, Camarca et al. have demonstrated that intestinal T cells 
from adult patients with celiac disease recognized a heterogeneous population of gluten 
peptides and only 50% of Italian patients with celiac disease recognized the 33-mer poly-
peptide (57-89) containing both the α-I and α-II epitopes (255). In addition to these studies 
on intestinal T cells, Tye-Din et al. have demonstrated that peripheral blood T cells from 
adult patients recognize several other gluten peptides than those containing the previous-
ly reported immunodominant epitopes (256). 
Although oral gluten challenge has been proven to be a non-invasive approach to in-
vestigate the peripheral blood immune response to gluten in adult patients with celiac 
disease it is not favourable to perform it in children (257). Circulating gliadin specific 
T-cell responses in children with celiac disease have not been studied widely. One recent 
study demonstrated that circulating T cells specific for various deamidated gliadin pep-
tides can also be detected in a high percentage of children with newly diagnosed celiac 
disease (258). 
2.4 DIAGNOSIS OF CELIAC DISEASE
2�4�1 Celiac disease antibodies
2�4�1�1 Reticulin and endomysial antibodies 
Antireticulin antibodies (ARA) were the first autoantibodies to be associated with celiac 
disease (22,23). The ARA test was introduced as a first serological diagnostic assay for 
celiac disease in 1977 and is routinely performed as an immunofluorescence assay on 
rat tissue (24). The assay measures both IgA and IgG class antibodies that are directed 
against reticular fibers of endomysium, a tissue structure of smooth muscle fibers. Nowa-
days, the ARA assay is no longer recommended as more sensitive and specific tests have 
been developed (21,25,26).
Endomysial antibodies (EmA), in turn, were discovered in 1983 (27). EmA is still con-
sidered the gold standard of celiac disease serological tests, although it measures the 
same antigen as the later developed tTGA assay (see 2.4.1.2) (27,259). The specificity of the 
EmA method in the diagnosis of celiac disease in adults is close to 100% both in treated 
and untreated patients but its sensitivity is lower. Several studies have shown that up to 
20% of patients with celiac disease are negative for EmA (260-264). The main drawbacks 
of the EmA method are that it is laborious, time-consuming and its interpretation can be 
somewhat subjective.
2�4�1�2 Tissue transglutaminase antibodies (tTGA)
The serological screening of celiac disease has been mainly been based on measuring IgA 
class tTGA ever since tTG was discovered as a major autoantigen of celiac disease in 1997 
(28). tTG is a calcium dependent enzyme of the protein-glutamine γ-glutamyltransferas-
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es family and can be found expressed in several tissues, such as heart, liver, skin and the 
small intestine (265,266). The small intestinal form of tTG, important in celiac disease, 
has also been named TG2, whereas the epidermal form of tTG, important in Dermatitis 
herpetiformis, has been named TG3 (267,268). tTG crosslinks proteins through glutamine 
residues thereby creating inter- and intramolecular bonds that are highly resistant to pro-
teolysis (269,270). Moreover, tTG catalyzes the deamidation of glutamine residues to glu-
tamic acid, a mechanism that is central for the pathogenesis of celiac disease (see 2.3.3.2) 
(216,271). 
tTGA tests have been shown to have both a high sensitivity and a specificity in the di-
agnosis of celiac disease (21,272). However, the diagnostic performance of the tTGA assay 
is highly dependent on the methodology used. It has been reported that the solid phase 
method, used in the radiobinding immunoassays and the liquid phase method, used in 
the ELISA assays may differ in their sensitivity and specificity, especially in the measure-
ment of IgG class tTGA (273,274). Thus the IgG class tTGA may perform with a lower 
sensitivity than IgA class tTGA, and it is only recommended to be used in the diagnosis 
of patients with selective IgA deficiency (21). Several studies have also demonstrated that 
tTGA levels correlate well with the histological changes observed in the intestinal muco-
sa, with higher levels observed in subjects with more severe pathology (275-277). Diag-
nosis of celiac disease in children is also mainly based on measuring tTGA (21,278,279). 
In young children, specifically in those under 2 years of age, tTGA may have a lower 
sensitivity (279-282). Moreover, it has been shown that tTGA seropositivity in children 
may be transient and some of the tTGA positive children may turn seronegative despite 
continuous gluten exposure (283). 
2�4�1�3 Anti-gliadin antibodies and deamidated gliadin peptide antibodies (anti-DGP)
Antibodies to gliadin were described already in 1958 (20). After the enzyme-linked immu-
nosorbent assay (ELISA) method for measuring gliadin antibodies (AGA) was described 
in the early 1980s, both IgA and IgG class AGAs have been widely used in the diagnosis 
of celiac disease, in both adults and children (19,284-286). Later studies have demonstrat-
ed that gliadin antibodies also appear in many other disorders than celiac disease leading 
to poor specificity of the assay. Therefore, AGA is nowadays not recommended for celiac 
disease diagnostics (21,278,287-290). However, although AGA has been shown to per-
form with low specificity, it may still be useful in the diagnosis of celiac disease in some 
cases in children under 2 years of age (291-293).
The T-cell response to deamidated gliadin peptides was described at the same time as 
tTG was demonstrated to be an autoantigen of celiac disease (28,216). Antibodies against 
these deamidated peptides (anti-DGP), as well as the older AGA are produced against 
food-derived antigens, which is in contrast to ARA, EmA and tTGA that all are produced 
against self-tissue structures. Assays for detecting IgA and IgG class antibodies to deami-
dated gliadin peptides have been developed most recently and have largely replaced the 
conventional AGA tests (29,294,295). The IgG anti-DGP assay has been shown to be at least 
as useful or even superior as IgG tTGA in the diagnosis of celiac disease in both adult and 
pediatric patients with selective IgA deficienc (296,297). Moreover, the IgG anti-DGP may 
be the only positive serological marker for celiac disease in older patients (298).
Several studies have demonstrated that parallel testing for both IgG anti-DGP antibod-
ies and IgA tTGA has the best specificity in screening for celiac disease in all age groups 
(272,299-301). Specifically, the IgG anti-DGP assay has shown high specificity in both 
adults and children with celiac disease (299,300,302,303). Moreover, IgG anti-DGP has 
been reported to be at least as useful as tTGA for detecting celiac disease in very young 
children (297,302). 
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Anti-DGP antibodies may also be the first serological markers of the onset of celiac 
disease (30,295). It has been demonstrated that anti-DGP antibodies may appear up to 
a year earlier than tTGA seropositivity in some children (30). Moreover, anti-DGP anti-
bodies have been shown to turn negative faster than tTGA after the start of a gluten-free 
diet, and they can thus be useful for monitoring diet compliance and as an indirect in-
dicator of the mucosal recovery (300,302,304-306). It has been demonstrated that IgG 
anti-DGP antibodies together with the tTGA assay have a high negative predictive value 
in children with celiac disease on a gluten-free diet. Therefore, the use of these two sero-
logical tests in follow-up would omit the need for repeat duodenal biopsy in the majority 
of patients (307).
2�4�2 Small-intestinal biopsy
The European Society of Paediatric Gastroenterology and Nutrition (ESPGHAN) has 
published diagnostic criteria of celiac disease for pediatric patients since 1969 (308). The 
first criteria adopted required a sequence of three small intestinal biopsies, first during 
ongoing gluten containing diet, second during the gluten-free diet and third after gluten 
rechallenge. These diagnostic criteria have since been revised and new ESPGHAN guide-
lines published in 2012 indicate that symptomatic children that show tTGA levels at least 
10 times above normal, are positive for EmA as well as HLA-DQ2 or -DQ8 no longer need 
to undergo duodenal biopsies to confirm the diagnosis of celiac disease (21). No unified 
criteria in adult patients have been published, and thus the diagnosis of celiac disease in 
adults usually still requires a duodenal biopsy after serological screening. The classifica-
tion of pathological changes in the duodenal mucosa is based on the Marsh criteria (31). 
The diagnostic criteria include typical changes of small intestine, crypt hyperplasia and 
villous atrophy, as well as an increased number of intraepithelial lymphocytes. In addi-
tion, the early stage with positive serology and increased IELs but not hyperplasia and 
villous atrophy in the biopsies has been categorized as potential celiac disease (309). In 
children with a family history of celiac disease potential celiac disease has been shown 
to precede the later onset of the disease whereas in adult patients it performs often inde-
pendently from celiac disease and the histological changes of the small intestinal mucosa 
do not develop (310,311). Another method, which uses the Watson capsule, also enables 
obtaining a single biopsy sample of the small intestinal wall. It is mainly used in children 
in place of upper GI endoscopy. In capsule endoscopy, a video capsule is swallowed to 
get photographs of the small intestine. This serves as an alternative method for the eval-
uation of celiac disease. Even though macroscopic pathologic changes of the intestinal 
mucosa characteristic of celiac disease can be identified by capsule endoscopy, its main 
limitation is the lack of ability to perform a biopsy. Therefore, capsule endoscopy in di-
agnosis of celiac disease is limited to patients to whom upper endoscopy is not suitable. 
Repeated monitoring of the decrease in celiac disease-associated antibodies during the 
first year is recommended for the assessment of response to the treatment and adherence 
to gluten-free diet in all patients (21,135). The recommendation of follow-up biopsies var-
ies depending on the country, or even the clinician in charge. However, repeted duodenal 
biopsy should be considered at least in patients with celiac disease who are symptomatic 
on a gluten-free diet or have an increased risk of other complications (21,135).
2�4�3 Genetic screening
Genetic analyses are not routinely performed in all individuals with a clinical suspicion 
of celiac disease. HLA-genotyping for the high-risk HLA-DQ2 and HLA-DQ8 alleles has 
a high negative predictive value and it has been mainly used to rule out celiac disease 
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and as a further diagnostic tool in cases where the diagnosis is equivocal. HLA-DQ2 and 
-DQ8 genotyping is recommended for individuals with suspected celiac disease but who 
fail to respond to a gluten-free diet as well as for self-treated patients on a gluten-free 
diet who have never been appropriately tested for celiac disease before commencing the 
diet (135). HLA-genotyping is also recommended to rule out celiac disease in individuals 
with a high risk because of first-degree relatives with the disease. HLA-DQ2 and -DQ8 
genotyping is recommended specifically for those pediatric patients with a strong clinical 
suspicion of celiac disease who have high celiac disease-specific antibody levels and for 
whom small intestinal biopsies are not going to be performed (21). As a result of the new 
recommendations by ESPGHAN stated above, the significance of HLA-DQ2 and -DQ8 
genotyping is likely to increase in the future and the HLA-screening could be used before 
tTGA test as suggested by Björck et al. (312,313).
2�4�4 New diagnostic tools
Serological tests are often used in the primary diagnosis and clinical follow-up of celi-
ac disease patients, but in some cases their sensitivity is not sufficient. A recent study 
demonstrated that 2–3% of celiac disease patients are seronegative for all celiac disease 
antibodies tested and have remarkably low antibody levels or fluctuating seropositivi-
ty. Therefore tests, other than those based on serological assays are needed to improve 
diagnostics of celiac disease (36). Overall, there is a trend for emphasizing non-invasive 
methods in both the diagnosis and follow-up of celiac disease. Moreover, there is a need 
for the development of new methods to detect patients at an early stage of the disease 
when histological changes are not yet detectable. Sollid and co-workers have studied 
the potential of identifying circulating and intestinal gliadin-specific T cells by an ele-
gant tetramer staining method as a novel diagnostic approach (16,251,314). They recent-
ly demonstrated that the HLA-DQ2-gliadin tetramer method from peripheral blood is 
a sensitive approach for detecting possible celiac disease in most adult patients (314). 
They also showed that the frequency of intestinal gliadin-specific T cells, as detected by 
tetramer staining, correlates with the degree of histological damage in the gut mucosa as 
well as with serum IgA tTGA levels, and therefore this could provide a supplementary 
diagnostic aspect (251).
2.5 TREATMENT OF CELIAC DISEASE
2�5�1 Gluten-free diet
The only current treatment for all forms of celiac disease is a life-long gluten-free diet, 
where wheat and related cereals, barley and rye, are avoided. In Dermatitis herpetiformis 
the drug dapson is often also needed for a clinical response (315). Several studies have 
shown that extraintestinal manifestations of celiac disease may also disappear during 
gluten-free diet (316-318). The efficacy of the gluten-free diet is critically dependent on the 
motivation of the patient. It is known that nonresponsive or refractory celiac disease is of-
ten caused by inadequate adherence to the diet. In a majority of the patients, pathological 
changes in the small intestinal mucosa are healed and the levels of celiac disease-related 
antibodies significantly decreased after one year of treatment. However, some individu-
als do not adequately respond to the gluten-free diet, a condition referred to as refractory 
celiac disease (319). 
Since the prolamin structure of avenin in oat differs from that of gliadin in wheat and 
gliadin-like proteins in barley and rye, several studies have shown that oat may be used 
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in the diet of celiac disease patients. The safety of oat has been confirmed both in adult 
and pediatric patients (320-323). However, there is also evidence that not all patients tol-
erate oat in the diet and the consumption of oat may even lead to villous atrophy (324). 
2�5�2 Non-dietary treatments
It is often challenging and expensive to strictly follow a life-long gluten-free diet. Re-
search on non-dietary treatments has been active in recent years and some of the inves-
tigated approaches have shown promising results (325). One option to avoiding dietary 
gluten is the neutralization of gluten. This was shown in a study where a synthetic copo-
lymer neutralized bound gluten and the gluten-induced effects both in mice and human 
duodenal tissue ex vivo (326). Oral protease enzymes, so-called glutenases, have been 
shown to increase the breakdown of proteolytically resistant gluten protein (327). Oral 
proteases are a promising option for non-dietary treatment of celiac disease, and some of 
them have been examined already in a phase II clinical trial (328,329). Another alternative 
way to avoid the detrimental reaction of dietary gluten is the inhibition of deamidation 
by using specific antagonists (330). A recently published study demonstrated that tTG 
inhibitors reduced gliadin-induced toxicity both in in vitro as well as in ex vivo assays 
employing biopsy cultures (331). Vaccines targeting the pathogenic T-cell response in ce-
liac disease have also been studied recently. Peptide-specific immunotherapy to induce 
tolerance towards gluten has been demonstrated in mice (332). Peptide-specific immuno-
therapy has been shown to be safe in humans but the major limitation of this approach in 
celiac disease is that the immunodominant T-cell epitopes responsible for pathogenesis 
are not yet fully defined and the tools to monitor the vaccine-associated immune response 
are still lacking (332). Importantly, all of the options currently considered for non-dietary 
treatment are more or less supplementary to the gluten-free diet. For example, it has been 
estimated that the oral gliadin specific proteases may eliminate only up to two grams of 
daily gluten, not the entire gluten intake (329).
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3 Aims of the study 
 I to clarify the potential of detection of gliadin-specific T cells in the peripheral 
blood for the diagnosis of celiac disease in children (I),
 II to evaluate the TR-IFMA assay for detecting antibodies to deamidated gliadin 
peptide in the diagnosis of celiac disease in children, and to analyze the timing 
of the development of anti-DGP positivity as compared to tTGA seropositivity 
(II),
 III to prospectively analyze the development of gliadin-specific immune responses 
by following the emergence of tTGA and anti-DGP antibodies and peripheral 
gliadin-specific T-cell responses in children at a high genetic risk for celiac 
disease (III).
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4 Experimental procedures
4.1 STUDY SUBJECTS
4.1.1 Children with confirmed celiac disease (I-II) 
Altogether 92 children with biopsy-confirmed celiac disease from two different cohorts 
were analyzed in this study. Forty-four of the 92 children with celiac disease (23 girls 
and 21 boys) were examined because of a clinical suspicion of celiac disease at the De-
partment of Pediatrics of the Kuopio University Hospital (clinical cohort). Blood samples 
were taken during the clinical visit, at the time of the biopsy, before starting gluten-free 
diet. Forty-three of these 44 children tested positive for tTGA, one of the children was not 
tested for tTGA but was highly positive for EmA. The diagnosis of celiac disease was con-
firmed by small intestinal biopsy at a median age of 6.3 years (range 1.2-15.0) (see 4.2.3). 
The results of the histological changes in the small intestine biopsy samples in the clinical 
cohort are shown in Table 1. Thirty-four (82.9%) of the children genotyped were positive 
for the disease-associated HLA-DQ2 molecule (carried DQA1*05 and DQB1*02 alleles), 
four (9.8%) were HLA-DQ8 positive (DQB1*03:02) and two (4.9%) were positive for both 
HLA-DQ2 and -DQ8. HLA-typing was not performed in three of the children. 
The second cohort of children with celiac disease (DIPP cohort) consisted of 48 subjects 
(17 girls and 31 boys) who were participating in the Finnish Type 1 Diabetes Prediction 
and Prevention study (DIPP) at the Turku and Tampere University Hospitals. Children 
in the DIPP follow-up study were screened for the HLA-associated genetic risk for T1D 
at birth and subsequently prospectively monitored for the development of T1D-associat-
ed autoantibodies. A subset of children positive for HLA-DQ2 (DQA1*05 and DQB1*02 
alleles) or HLA-DQ8 (DQB1*03:02) was also monitored for the development of tTGA pos-
itivity, and if the child was tTGA seropositive in two consecutive samples they were bi-
opsied to confirm the diagnosis of celiac disease. The results of the histological changes 
in small intestine biopsy samples in the DIPP cohort are shown in Table 2. Blood samples 
from the children in the DIPP cohort were collected every 3 to 6 months from birth until 
2 years of age and every 6 to 12 months thereafter. Seventeen of the 48 (35.4%) DIPP chil-
dren that developed celiac disease were positive for HLA-DQ2 (DQA1*05 and DQB1*02), 
13 (27.1%) were positive for both HLA-DQ2 and -DQ8 and 19 of them (39.6%) were pos-
itive for HLA-DQ8 (DQB1*03:02). The median age at the time of diagnosis was 5.0 years 
(range 1.6-11.9 years). The serum sample used for the analysis of anti-DGP assay sensi-
tivity and specificity was either taken at the time of biopsy (n=60) or at the last available 
follow-up visit before the biopsy (n=32, median 31 days, range 1-252 days).
4�1�2 Healthy controls (I-II)
The control group consisted of 82 healthy children (33 girls and 49 boys) carrying the 
celiac disease-associated HLA alleles (HLA-DQ2 and/or HLA-DQ8). The control children 
participated in the Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabe-
tes (FINDIA) follow-up study (333). Twenty-seven of the controls (32.9%) were positive 
for HLA-DQ2, 8 (9.8%) were positive for both HLA-DQ2 and -DQ8 and 47 of the children 
(57.3%) were positive for HLA-DQ8. All of the control children were tested negative for 
tTGA. Sixty-four of the children were used as controls in study I and their median age 
at the time of sampling was 5.1 years (range 4.0–6.1). All of the 82 control children were 
analyzed in study II at a median age of 6.0 years (range 3.0–6.8).
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4�1�3 Children with a high genetic risk for celiac disease (III)
Children with a high genetic risk for celiac disease were recruited from the Kuopio Uni-
versity Hospital and the Kätilöopisto Maternity Hospital in Helsinki for prospective fol-
low-up. Parents of newborns were first met at the maternity hospital and they were briefly 
informed about the study protocol. Altogether 2013 newborn children were screened for 
the presence of HLA-DQB1*02 and -DQA*05 alleles, which are associated with the high-
est risk for celiac disease. The families were informed of the results of the HLA-screening 
by a phone call when the child was 1 to 2 weeks old. A total of 339 of the children had the 
appropriate alleles (16.8%) and 291 of these children were followed prospectively. New-
born children were randomized to a dietary intervention group and a control group. The 
intervention group was given specific nutritional counseling with the aim to time gluten 
introduction to diet optimally, as described in chapter 4.3. Blood samples were collect-
ed at the ages of 9, 12, 18, 24 and 36 months from all children and also at the age of 48 
Table 1. Histological results of the duodenal biopsies in the clinical cohort.
Clinical 
cohort 
(n=44)
 
 
Study
 
Histology stage  
of villous atrophy
Clinical 
cohort 
(n=44)
 
 
Study
 
Histology stage  
of villous atrophy
1 II total 23 II subtotal
2 II total 24 II subtotal
3 II total 25 II subtotal
4 II total 26 I,II subtotal
5 II total 27 I,II subtotal
6 II total 28 II partial
7 II total 29 II partial
8 II total 30 II partial
9 II total 31 II partial
10 II total 32 II partial
11 II total 33 II partial
12 II total 34 II partial
13 I, II total 35 I,II partial
14 I, II total 36 I,II partial
15 I,II total 37 I,II partial
16 I,II total 38 I,II partial
17 I,II total 39 I,II partial
18 I,II total 40 I,II partial
19 I,II total 41 I,II partial
20 I,II total 42 II stage not determined
21 II total 43 II stage not determined
22 I,II total 44 I,II stage not determined
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months from 85 children at the Kuopio University Hospital. All of the 291 children were 
followed for tTGA and anti-DGP antibodies. The results of the tTGA test were reported 
to families, and if the child was tTGA seropositive the families were offered an option for 
small intestinal biopsy. Although no clinical cut-off value for tTGA was determined, in 
most of the cases the small intestinal biopsy was performed if the child had high (over 50 
IU/ml) tTGA titer whereas children with low tTGA titer were followed with serological 
analyses. Children with anti-DGP seropositivity only were not biopsied, according to the 
original study plan. The 85 children followed until 48 months of age were also analyzed 
for peripheral gliadin specific T-cell responses at the same sampling points as the serolog-
ical analyses. Due to the small volume of blood obtained in some samples, the serological 
analyses were given priority and thus T-cell assays were not performed in every sampling 
point in all of the children studied.
Table 2. Histological results of duodenal biopsies in the DIPP cohort.
DIPP 
cohort 
(n=48)
 
 
Study
Histology stage of  
villous atrophy
DIPP 
cohort 
(n=48)
 
 
Study
Histology stage of  
villous atrophy
1 II partial 25 II subtotal
2 II partial 26 II subtotal
3 II partial 27 II subtotal
4 II partial 28 II subtotal
5 II partial 29 II subtotal
6 II partial 30 II subtotal
7 II partial 31 II subtotal
8 II partial 32 II total
9 II partial 33 II total
10 II partial 34 II total
11 II partial 35 II total
12 II partial 36 II total
13 II partial 37 II total
14 II partial 38 II total
15 II partial 39 II total
16 II subtotal 40 II total
17 II subtotal 41 II total
18 II subtotal 42 II total
19 II subtotal 43 II total
20 II subtotal 44 II stage not determined
21 II subtotal 45 II stage not determined
22 II subtotal 46 II stage not determined
23 II subtotal 47 II stage not determined
24 II subtotal 48 II stage not determined
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4.2 METHODS 
4�2�1 HLA-genotyping (I-III)
The presence of HLA-DQA1 and -DQB1 alleles in all patients and controls were ana-
lyzed using sequence-specific oligonucleotide hybridization reactions, as previously de-
scribed (334-336).
4�2�2 Celiac disease-associated antibodies (I-III)
All serum samples were kept frozen at -80°C until analyzed for celiac disease-associated 
antibodies. The IgA and IgG class antibodies to a synthetic deamidated gliadin peptide 
(anti-DGP) (29) were measured by a solid-phase lanthanide-based, time-resolved immu-
nofluorometric assay (TR-IFMA) using Europium-labeled anti-human IgA and Samar-
ium-labeled anti-human IgG, as described earlier (295) (II-III). Commercial ELISA (en-
zyme-linked immunosorbent assay) -based recombinant human Celikey kit was used to 
measure IgA class tTGA in children with celiac disease and in controls (Phadia, Freiburg, 
Germany) (I-III) according to manufacturer’s protocol. Values > 8 U/ml were considered 
positive, as suggested by the manufacturer. 
4�2�3 Small intestinal biopsies (I-III)
The diagnosis of celiac disease in all patients was confirmed by small intestinal biopsy. 
Duodenal biopsy was taken with the Watson capsule method in all of the 44 children 
examined for clinical suspicion of celiac disease at the Kuopio University Hospital (I-II). 
Only one biopsy sample from duodenum, after bulbus but before the ligament of Treitz, 
was taken from each subject with this method. Endoscopic biopsy was done after general 
anesthesia and 3 to 4 biopsy samples were taken from each subject in the DIPP cohort, 
as well as from children biopsied in the follow-up study at the Kuopio University Hos-
pital or at the Kätilöopisto Maternity Hospital in Helsinki (III). One of the samples was 
taken from the bulbus and two or three samples from duodenum. The diagnosis of celiac 
disease was based on the International Academy of Pathology classification in which the 
representativeness of the biopsy sample, the presence of villous atrophy and its severity 
and crypt hyperplasia in the intestinal mucosa biopsies are assessed. Although the Marsh 
classification (31) was not routinely used for the categorization of biopsy results, namely 
the number of IELs was not routinely recorded in the pathology report, nearly all of the 
children with biopsy-confirmed celiac disease belong to the Marsh class III. Thus, the 
stage of villous atrophy was categorized as partial to total (Table 1 and 2). Staining for 
CD3+ T cells and gamma delta T cells was also not performed for all of the cases. 
4�2�4 T-cell proliferation assays using the CFSE dilution method (I, III)
The development of a gliadin-specific immune response was also analyzed by determin-
ing peripheral T-cell responses to deamidated and native gliadin. Antigen-specific T-cell 
responses were analyzed in vitro from freshly isolated peripheral blood mononuclear 
cells (PBMC) in children with newly-diagnosed celiac disease and in healthy controls (I), 
and in children with high genetic risk for celiac disease (III). PBMCs were labeled with 
carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen, Molecular Probes, 
USA) and suspended in culture medium (RPMI 1640 supplemented with 5% inactivated 
human AB serum (Sigma Aldrich), 2 mM L-glutamine, 20 μM 2-mercaptoethanol, 1 mM 
natrium pyruvate, nonessential amino acids, 100 IU/ml penicillin, 100 μg/ml streptomy-
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cin and 10 mM HEPES (all from Lonza, Verviers, Belgium) at 106/ml and stimulated with 
different antigens in a volume of 200 μl in a 96-well round-bottomed plate (Costar, Corn-
ing Incorporate USA). Cells were maintained at 37°C and 5% CO2 in 6 to 8 equal wells per 
antigen for 10 days, with the exception of PHA in 4 equal wells.
4�2�5 Antigens used in the T-cell proliferation assays (I, III)
The T-cell proliferation assay was performed similarly in studies I and III. Purified tet-
anus toxoid (TT) was used as an independent control antigen at a final concentration of 
1 μg/ml (National Institute of Health and Welfare, Helsinki, Finland). Purified phyto-
haemagglutinin (PHA) was used as a mitogen control of cell functionality at a final con-
centration of 2 μg/ml (Remel, UK). Deamidated gliadin antigen was prepared as follows. 
First, native gliadin from wheat powder (Sigma Aldrich, St. Louis USA) was dissolved in 
dimethyl sulfoxide (DMSO) and diluted with 4 mM CaCl2 solution (CaCl2 dissolved in 
PBS) to a concentration of 4 mg/ml. tTG (from guinea pig liver, Sigma Aldrich, St. Louis 
USA) was dissolved in PBS to a concentration of 0.8 mg/ml. Deamidation of gliadin with 
tTG was accomplished by incubation of gliadin and tTG in a final volume of 100 μl (25 
μl gliadin-dilution, 25 μl tTG-dilution and 50 μl PBS) for 2 h at 37°C. Finally 20 μl of this 
mixture per 1 ml culture medium was used to stimulate cells, corresponding to a con-
centration of 20 μg/ml of deamidated gliadin. Native gliadin alone was used at a final 
concentration of 10 μg/ml and the tTG alone at 2 μg/ml. In study I, PBMCs were stim-
ulated also with 10 μg/ml of synthetic deamidated gliadin peptides QLQPFPQPELPY 
(Q12Y) and PQPELPYPQPELPY (P14Y) (purity >95%, GL Biochem, Shanghai, China), 
which contain the earlier reported immunodominant gliadin epitopes α-I and α-II, re-
spectively (17).
4�2�6 Flow cytometry analyses (I, III)
After 10 days of culture, replicate wells for each antigen were pooled, washed with 
ice-cold wash buffer (PBS, 2% FCS and 0.1% NaN3) and stained on ice for 20 min with 
the following antibodies: anti-CD4-PerCP-Cy5.5, anti-CD45RO-PE-Cy7, anti-CD45RA-
APC and integrin β7-PE (BD Pharmingen, San Jose, USA). Antigen-specific proliferation 
was analyzed by flow cytometry (FACS Canto II, Becton Dickinson, Mountain View, 
USA) using the FACSDiva software (BD). The percentage of proliferated CD4+ T cells 
was determined by gating the CD4+CFSElow subset and calculating its proportion of 
the total CD4+ cells. The cell division index (CDI) for different antigens was calculated 
as follows: the percentage of CD4+ CFSElow cells in stimulated cultures divided by the 
percentage of CD4+CFSElow cells in unstimulated cultures (337). Individual responses 
to an antigen were considered positive when the CDI was ≥ 2.0 and the difference in the 
percentage of CD4+CFSElow cells between stimulated and unstimulated cultures was 
at least 0.5%.
4�2�7 Statistical analyses (I-III)
All statistical analyses were performed by GraphPad Prism version 5.0 (GraphPad Soft-
ware, San Diego, CA, USA). The Mann-Whitney U-test (I-III) and Fisher’s exact test (I-III) 
were used to compare differences between groups when appropriate. Wilcoxon matched-
paired signed rank test was used to analyze the changes within a group (II). The Spear-
man rank correlation test was used to assess the correlation between two parameters 
(I, II). The cut-off values of the TR-IFMA anti-DGP assay for the highest sensitivity and 
specificity were determined by receiver operating characteristics (ROC) curves (II). The 
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Chi-Square test was used to compare whether the optimal gluten introduction between 4 
and 6 months was performed more often in the intervention or in the control group in the 
follow-up study (III). Two-tailed P-values of less than 0.05 were considered significant in 
all statistical analyses.
4.3 DIETARY INTERVENTION IN CHILDREN WITH A HIGH GENETIC 
RISK FOR CELIAC DISEASE (III)
Newborn children carrying the HLA-DQA1*05 and -DQB*02 alleles were randomized to 
an intervention and a control group by using a random number generator. The interven-
tion group was given specific nutritional counseling for the purpose of timing the intro-
duction of gluten to an optimal window between 4 and 6 months of age and while breast-
feeding was ongoing, as suggested by previous investigations (103,160,161,165,171,338). 
Families were advised to start the introduction of gluten-containing cereals with one tea-
spoon on the first day, two teaspoons on the second day and so on, gradually increasing 
the amount of gluten up to a maximum of one deciliter during the first week. The families 
were briefly informed by a phone call about gluten introduction when their child was 1.5 
months old, and given a more detailed counseling in person on starting solid foods when 
the child reached 3.5 months of age. The control group received normal nutritional coun-
seling given to all Finnish families at the child health clinics. Nutritional information was 
collected similarly in both groups using dietary questionnaires and phone calls (at the age 
of 1–2 week, 1.5 months, 3.5 months, 6 months and 9 months). 
4.4 ETHICS (I-III)
The ethical committees of the participating university hospitals in all substudies approved 
the study protocol: Kuopio University Hospital (I-III), Helsinki University Hospital (I-II) 
and Turku University Hospital (II). Written informed consent was obtained from parents/
guardians (I-III) and from children over 7 years of age (I-II).
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5 Results
5.1 DEVELOPMENT OF tTGA SEROPOSITIVITY AND CELIAC  
DISEASE IN CHILDREN WITH A HIGH GENETIC RISK (III)
Children with a high genetic risk for celiac disease (all positive for HLA-DQ2) were fol-
lowed prospectively for the development of tTGA until the age of 3 or 4 years. The cu-
mulative tTGA seropositivity was 6.5% (19 of 291 children) during the follow-up. The 
median age at tTGA seroconversion was 24 months (range 18–48 months) and there were 
three children who converted to tTGA seropositivity at the age of 18 months (Original 
article III, Figure 1). Celiac disease was diagnosed in altogether 9 of the 291 children at the 
median age of 3.5 years (range 2.6–4.2). The cumulative incidence of celiac disease by the 
age of 3 to 4 years was 3.1% (Original article III, Figure 3). A total of 2.4% of the children 
had transient tTGA seropositivity as they converted back to tTGA seronegative during 
the follow-up. The median level of tTGA at the time of seroconversion was significantly 
higher in children with confirmed celiac disease than in those with transient tTGA se-
ropositivity (p=0.008, median 9.5 IU and 100.0 IU, respectively, Mann-Whitney U-test). 
Eighteen of all 19 tTGA seroconverted children as well as all of the 9 children diagnosed 
with celiac disease were girls. 
5.2 EVALUATION OF THE TR-IFMA ANTI-DGP ASSAY (II)
In order to evaluate the performance of the in-house TR-IFMA anti-DGP assay in pedi-
atric patients, serum samples were analyzed from children with celiac disease and from 
healthy controls. All of the children with celiac disease were positive for tTGA and all of 
the healthy controls tested negative for tTGA. Serum samples were first analyzed at the 
time of diagnosis of celiac disease or at the latest available sample before the diagnosis. As 
expected, the median levels of both IgA and IgG class anti-DGP antibodies were signifi-
cantly higher in celiac disease patients than in healthy controls (p<0.0001, Mann-Whitney 
U-test) (Original article II, Figure 1A). The sensitivity and specificity of the assays were 
calculated and the optimal cut-off values for anti-DGP seropositivity were determined 
from ROC-curves (Figure 5A and 5B). Based on the ROC curves the optimal cut-off val-
ue for IgA anti-DGP positivity was 153 AU with a sensitivity of 92.4% and specificity of 
97.6%. The optimal cut-off value for IgG anti-DGP positivity was 119 AU, with a sensitiv-
ity of 98.9% and specificity of 97.6%.
5.3 ANTI-DGP ANTIBODY POSITIVITY AT THE  
DIAGNOSIS OF CELIAC DISEASE (II, III)
The frequency of seropositivity to a synthetic deamidated gliadin peptide (anti-DGP as-
say) at the diagnosis of celiac disease was analyzed retrospectively in the DIPP cohort (II) 
and prospectively in the follow-up study of children with a high genetic risk for celiac 
disease (III). Overall, the anti-DGP assay performed with a high sensitivity, as all except 
one of the children with celiac disease in study II were either IgA or IgG anti-DGP posi-
tive at the time of diagnosis or at the latest sampling before the diagnosis of celiac disease: 
85 of the 92 children (92.4%) were IgA anti-DGP positive, 91 of 92 (98.9%) were IgG an-
ti-DGP positive and 84 of 92 (91.3%) were both IgA and IgG anti-DGP positive at the time 
of diagnosis. Only two of the 82 tested healthy controls were positive for IgA anti-DGP 
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and two other children positive for IgG anti-DGP, which demonstrates that both the IgA 
and IgG class anti-DGP assays have also a high specificity. 
In study III, all except one of the children (18 of 19, 91.7%) who converted tTGA sero-
positive were also positive for anti-DGP antibodies at least in one sampling point during 
the follow-up. All of the tTGA seropositive children with confirmed celiac disease were 
both IgA and IgG anti-DGP positive at the time of tTGA seroconversion, whereas 5 of 
the 8 children (62.5%) with transient tTGA seropositivity were anti-DGP IgG but not IgA 
positive at the time of tTGA seroconversion (Original article III, Table II). Among children 
who remained tTGA seronegative during the follow-up some developed anti-DGP anti-
bodies. The percentage of IgA and IgG anti-DGP positivity in tTGA seronegative children 
during the follow-up varied between 0.4–1.4% and 4.1–10.0%, at various age points, cor-
responding to a specificity of 98.6-99.6% and 90.0-95.9%, for IgA and IgG anti-DGP, re-
spectively (Original article III, Figure 4A and B). Most of the tTGA seronegative children 
who developed anti-DGP antibodies were positive only at one sampling point and turned 
seronegative in the subsequent sample (36 of 272, 13.2%) but 20 of 272 children (7.4%) 
were repeatedly IgA or IgG anti-DGP positive (at least in two sampling points). 
5.4 IgG-CLASS ANTI-DGP ANTIBODIES PRECEDE  
tTGA SEROCONVERSION (II, III)
In the retrospective analysis of the DIPP cohort (II), anti-DGP positivity preceded tTGA 
seropositivity in 72.9% (35 of 48) of children who were later diagnosed with celiac disease. 
In almost half (21 of 48, 43.8%) of the children with celiac disease only IgG anti-DGP was 
positive before tTGA seropositivity, 27.1% of the children (13 of 48) were both IgA and 
IgG anti-DGP positive and only one of the children was positive for IgA but negative for 
anti-DGP before the appearance of tTGA. Anti-DGP antibodies were detected a median of 
Figure 5. (A) Receiver operating characteristics (ROC) of IgA anti-DGP in all children at or 
just before diagnosis of celiac disease: area under the curve = 0.99 (95% CI 0.98 – 1.00). 
(B) Receiver operating characteristics (ROC) of IgG anti-DGP in all children at or just before 
diagnosis of celiac disease: area under the curve = 0.99 (95% CI 0.99-1.00)
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1.0 year (range 0.2-7.6) before tTGA seroconversion. Sixteen of these 35 children (45.7%) 
had IgA or IgG anti-DGP in at least two samples taken before tTGA seroconversion. In 19 
of the children with celiac disease (54.3%) anti-DGP antibodies were positive once before 
tTGA seroconversion. The remaining 13 of 48 (27.1%) of the children converted anti-DGP 
positive at the time of tTGA seroconversion. The levels of both IgA and IgG anti-DGP an-
tibodies were significantly higher in the last positive serum sample before the diagnosis 
of celiac disease than in the first positive serum sample (p=0.0013 and p=0.0004, respec-
tively, Wilcoxon matched-paired signed rank test) (Original article II, Figure 3A and B).
In the prospective study, IgG anti-DGP positivity preceded tTGA seroconversion in 
more than half of the children (5 of 9, 55.5%) that developed tTGA seropositivity and 
were later diagnosed with celiac disease, a median of 1.0 year earlier (range 0.5-1.5) (Orig-
inal article III, Table II). In one of the children with confirmed celiac disease IgA class 
anti-DGP antibodies also appeared 1.0 year earlier than tTGA seropositivity. In addition, 
in the group of children with transient tTGA seropositivity, over half of the cases (5 of 8, 
62.5%) developed IgG anti-DGP positivity a median of 1.2 year earlier (range 0.5-2.9) than 
tTGA (Original article III, Table II). Two of the children with transient tTGA seropositivity 
were IgG anti-DGP positive at two sampling points before tTGA seroconversion.
5.5 PRESENCE OF GLIADIN-SPECIFIC CD4+  
T CELLS IN THE PERIPHERAL BLOOD (I, III)
Gliadin-specific T-cell responses in peripheral blood were analyzed in children with celi-
ac disease at the time of diagnosis and also followed prospectively in children with high 
genetic risk for celiac disease (I, III). The frequencies of observed peripheral blood T-cell 
responses to all antigens tested in studies I and III are shown in Table 3. Circulating CD4+ 
T cells specific to deamidated gliadin (gTG) were detectable in more than half of the chil-
dren with active celiac disease as 11 of 20 (55.5%) of the patients had a positive response to 
gTG compared to 15 of 67 (22.4%) of the healthy controls (p=0.007, Fisher’s exact test). The 
criteria for a positive antigen-specific proliferative T-cell response is described in chapter 
4.2.6. The intensity of the proliferative responses to gTG was also significantly stronger 
in patients than in controls (p=0.02, Mann-Whitney U-test, Original article I, Figure 1) 
whereas there was no difference in the frequency of T-cell responses to native gliadin 
between patients and healthy controls (10.5% and 19.7%, respectively). The intensity of 
proliferative responses to native gliadin also did not differ between patients and healthy 
controls (Original article I, Figure 1). None of the children with celiac disease, and only 
3.6 % of the controls, had T-cell responses to tTG (Table 3). 
Altogether 85 children were followed prospectively for peripheral gliadin-specific 
T-cell responses in study III at the ages of 9, 12, 18, 24, 36 and 48 months. Altogether 306 
samples were analyzed during the follow-up. In total 40.5% of the children (17 of 42) had 
a positive T-cell response to gTG at the age of 9 months whereas only 20.0% of the chil-
dren (8 of 40) tested had a positive T-cell response to native gliadin at that age (Table 3). 
The percentage of positive gTG responses decreased during the follow-up to the level of 
22.2% at the age of 48 months, which is similar to the frequency detected in healthy con-
trols in study I (Table 3). T-cell responses to native gliadin decreased even more during 
the follow-up, down to the level of 7 to 9% (Table 3). 
In study I, the peripheral blood T-cell responses were also tested to the previously de-
scribed immunodominant T-cell epitopes α-I (Q12Y) and α-II (P14Y) of gliadin (17). None 
of the children with celiac disease showed a positive proliferative response to either of the 
gliadin peptides, and only 7.7% and 5.8% of the healthy controls had a positive response 
to the Q12Y and P14Y peptides, respectively (Table 3).
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5.6 EXPRESSION OF CD45RA-CD45RO+ MEMORY PHENOTYPE IN  
PERIPHERAL BLOOD GLIADIN-SPECIFIC CD4+ T CELLS (I, III)
Since gliadin-specific T-cell responses to deamidated and native gliadin were seen both 
in children with active celiac disease and in healthy controls, the cell surface phenotype 
of these cells was further analyzed (I). The expression of CD45RA and CD45RO was an-
alyzed in vitro to determine the frequency of memory (CD45RA-CD45RO+) CD4+ T cells 
within the proliferating cells. In children with confirmed celiac disease, the percentage 
of CD45RA-CD45RO+ cells among proliferating CD4+ T cells was significantly higher in 
stimulations with gTG than in those with native gliadin (p=0.024, Mann-Whitney U-test, 
Original article I, Figure 3B), whereas in healthy controls the percentage of CD45RA-
CD45RO+ cells in stimulations with both gTG and native gliadin were similar (p=0.35, 
Mann-Whitney U-test, Original article I, Figure 3B). The expression of memory markers 
on gliadin-stimulated CD4+ T cells was also analyzed in the follow-up study of geneti-
cally predisposed children (III). No differences in the percentages of CD45RA-CD45RO+ 
cells between stimulations with deamidated and native gliadin were observed in children 
with a high genetic risk for celiac disease during the follow-up (III). 
5.7 EXPRESSION OF Β7-INTEGRIN ON PERIPHERAL BLOOD  
GLIADIN-SPECIFIC CD4+ T CELLS WITH MEMORY PHENOTYPE (I, III)
The expression of β7-integrin, a gut-homing receptor, was analyzed in CD4+ T cells stim-
ulated with different antigens in vitro. The frequency of β7high cells was higher among 
proliferating CD4+ memory T cells stimulated with gTG (83.0%) than among CD4+ mem-
ory T cells stimulated with native gliadin (45.8%) in children with active celiac disease 
Table 3. Frequencies of positive proliferative responses to different antigens in children with 
celiac disease (CD), in healthy controls, and in children with a genetic risk for celiac disease 
followed prospectively.
Antigen
Study I Study III
CD  
children
(n=20)
 
Controls
(n=64)
Children positive for HLA-DQA1*05 and DQB1*02 (n=85)
9 
months
12 
months
18 
months
24 
months
36 
months 
48 
months
Positive/Analyzed
gTG 11/20 (55.0%)
15/64 
(23.4%)
17/42 
(40.5%)
18/56 
(32.1%)
16/52 
(30.8%)
15/55 
(27.3%)
18/59 
(30.5%)
10/45 
(22.2%)
Gliadin 2/19 (10.5%)
13/64 
(20.3%)
8/40 
(20.0%)
9/55 
(16.4%)
10/52 
(19.2%)
4/55 
(7.3%)
4/59 
(6.8%)
4/45 
(8.9%)
tTG 0/16 (0%)
2/55 
(3.6%)
2/30 
(6.7%)
0/39 
(0%)
1/40 
(2.5%)
0/42 
(0%)
0/48 
(0%)
3/38 
(7.9%)
TT 18/20 (90.0%)
53/64 
(82.8%)
26/32 
(81.3%)
29/39 
(74.4%)
23/41 
(56.1%)
28/43 
(65.1%)
41/48 
(85.4%)
23/38 
(60.5%)
Q12Y 0/15 (0%)
4/50 
(8.0%)
P14Y 0/15 (0%)
3/50 
(6.0%)
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(p=0.021, Mann Whitney U-test, Original article I, Figure 4). The frequency of β7high 
CD4+ memory T cells was similar among gTG (median 60.2%) stimulations and native 
gliadin (median 52.9%) in healthy control children (p=0.37 Mann-Whitney U-test). There 
was no difference in β7-integrin expression on proliferating CD4+ T cells stimulated with 
TT, used as an independent control, between patients and controls. The frequency of 
β7high cells was higher among proliferating CD4+ memory T cells stimulated with both 
deamidated (median 45.3%) and native gliadin (46.3%) than among CD4+ memory T cells 
stimulated with TT (29.7%) in children with a genetic risk for celiac disease (p<0.0001 and 
p=0.0002, respectively, Mann Whitney U-test) (Original article III, Figure 2C). 
5.8 DIETARY INTERVENTION (III)
The median age at gluten introduction in all 291 children followed prospectively in study 
III was 6.0 months (range 3.6-9.7 months). Gluten was introduced slightly earlier in chil-
dren who were given special nutritional counseling (see 4.3) than in control children (me-
dian 5.6 and 6.3 months, p<0.0001, Mann Whitney U-test). Gluten was introduced between 
the optimal window of 4-6 months in 147 of the 291 children (50.5%). This was performed 
significantly more often in the intervention group than in controls (71.5% and 43.1%, re-
spectively, p<0.0001, Chi-Square test). In 108 of the children (37.1%), gluten introduction 
was performed after 6 months of age and only in 3 children (1.0%), was gluten introduced 
before 4 months of age. In 14 children (4.8%) the age at which gluten was introduced was 
not reported. Further analyses of the effect of gluten introduction were performed only 
in those children who had gluten introduction between 4 and 6 months or after 6 months 
of age, regardless of whether they were included in the original intervention or control 
group. Altogether 51.2% of the children were breastfed during gluten introduction (149 
of 291 children) and in 25.4% (74 of 291 children) breastfeeding was not continued during 
gluten introduction. The remaining 23.4% were not categorized because of inadequate 
information (68 of 291 children). The amount of gluten introduced was reported inad-
equately in several questionnaires, and thus no further analysis was conducted on this.
5.9 THE EFFECT OF GLUTEN INTRODUCTION ON THE DEVELOPMENT 
OF GLIADIN-SPECIFIC IMMUNE RESPONSES (III)
The timing of gluten introduction did not have a significant effect on the development of ce-
liac disease. The cumulative incidences of tTGA seropositivity during the follow-up in chil-
dren who had gluten introduction between 4 and 6 months and in children who had gluten 
introduction after 6 months of age were 6.4% and 6.9%, respectively (p=0.525, Fisher’s exact 
test). Cumulative anti-DGP positivity at the age of 48 months in children who had gluten 
introduction between 4 and 6 months and in children who had gluten introduction after 6 
months of age was also equal (21.8% and 21.3%, respectively, p=0.383, Fisher’s exact test). 
Among the 85 children followed prospectively for peripheral blood gliadin-specific 
T-cell responses, gluten was introduced at a median age of 5.8 months (range 3.6-9.7). 
In 46 children (54.1%) gluten was introduced between 4 and 6 months of age and in 32 
children after 6 months of age (37.6%). In the remaining 5 children the age of gluten in-
troduction was not reported. Gluten introduction did not have a significant influence on 
the development of gliadin-specific T-cell responses. The percentages of positive T-cell 
responses to gTG in children who had gluten introduction between 4 and 6 months and 
in children who had it after 6 months of age were 56.5% and 68.8%, respectively (p=0.197, 
Fisher’s exact test).
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6 Discussion
The diagnosis of celiac disease is nowadays based on serological screening and subse-
quent confirmation by the detection of typical histological changes in duodenal biopsies. 
The duodenal biopsy is taken by upper GI endoscopy, which requires a general anesthe-
sia in pediatric patients and is somewhat an uncomfortable procedure. An alternative 
method for duodenal biopsy in children is a Watson capsule endoscopy, which in turn 
does not require anesthesia but allows taking only a single biopsy sample compared to 
upper GI endoscopy by with 3 to 4 samples can be collected. New criteria recently pro-
posed by The European Society for Paediatric Gastroenterology, Hepatology and Nu-
trition (ESPGHAN) emphasize the significance of serological testing in the diagnosis of 
celiac disease in children and suggest that the diagnosis can be based on high levels of 
celiac disease-specific antibodies, reducing the need for duodenal biopsy (21). Although 
serological screening has a central role in the diagnosis of celiac disease, it is known that 
T-cell mediated inflammatory processes in the intestinal mucosa are already ongoing 
when celiac disease-associated antibodies appear. The aim of this thesis was to determine 
whether gliadin-specific antibody and T-cell responses can be detected before the onset 
of the clinical disease by using immunological tests. For this purpose, celiac disease-asso-
ciated antibodies and gliadin-specific T-cell responses were analyzed in peripheral blood 
samples from children with active celiac disease at the time of diagnosis, and also pro-
spectively in children with a high genetic risk for the disease. 
6.1 THE DEVELOPMENT OF CELIAC DISEASE-ASSOCIATED ANTIBODIES
Serological screening has largely been based on the measurement of serum IgA tTGA, 
which has both high sensitivity and specificity in the diagnosis of celiac disease 
(272,302,303,339). tTGA may, nevertheless, perform with a lower sensitivity especially 
in young children under two years of age (297,302). It is also known that young children 
may have transient tTGA seropositivity and not all of the tTGA seropositive individuals 
will eventually develop clinical disease (340,341). In a recently published study it was 
shown that even up to 28% of children with T1D who developed tTGA seropositivity 
later became seronegative despite ongoing gluten consumption (342). EmA have been 
considered as the golden standard for the diagnosis of celiac disease as they perform with 
extremely high specificity. Although the method for detecting EmA is time-consuming, 
and the results depend on the quality and experience of the laboratory, the new criteria 
by ESPGHAN recommend the EmA test as a celiac disease-specific antibody test and 
tTGA for primary screening of celiac disease (21). Moreover, the ESPGHAN guidelines 
have emphasized the importance of antibody levels. Based on these recommendations, 
the duodenal biopsy may be avoided in children positive for tTGA at levels over 10 times 
the upper limit of normal and when a false-positive result has been excluded by positive 
EmA and positivity for HLA-DQ2 or HLA-DQ8 (21).
Assays for detecting IgA- and IgG-class antibodies to deamidated gliadin peptides 
(anti-DGP) have been developed most recently and are widely used because of their good 
sensitivity and specificity, especially in children. The sensitivity of IgA anti-DGP has been 
reported to range between 80.7% and 95.1% and that of IgG anti-DGP between 80.1% and 
98.6% (272). In several studies, the specificity of the IgG anti-DGP assay has been demon-
strated to be extremely high, both in adults and in children (299,300,302,303). The spec-
ificity has been reported to be up to 98.9% for IgG anti-DGP in adults and even 100% in 
children under 2 years of age (302,303). However, the reported sensitivity and specificity 
of anti-DGP antibodies has a wide range presumably due to the wide variety of methods 
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and commercial kits that have been used in these studies (272). Recent studies have indi-
cated that parallel testing for both tTGA and IgG anti-DGP antibodies may have the best 
specificity in the screening for celiac disease, both in adults and children (30,296). 
The performance of a TR-IFMA anti-DGP assay in the diagnosis of celiac disease in 
children was analyzed in study II. Serum samples from children taken at the time of 
diagnosis of celiac disease or the latest sample available before the diagnosis were ana-
lyzed in the DIPP cohort and in healthy, age- and HLA-matched controls. A ROC curve 
analysis demonstrated that the optimal cut-off value for IgA anti-DGP was 153 AU and 
for IgG anti-DGP 119 AU. All of the 92 children with celiac disease were either IgA or IgG 
anti-DGP positive. The cut-off values determined with pediatric samples in this study 
are very similar to the earlier reported cut-offs of 150 AU for both IgA and IgG anti-DGP, 
which are based on the analyses of adult serum samples (295) Only one of the children 
with celiac disease was not IgG anti-DGP positive and seven children were IgA anti-DGP 
negative, indicating sensitivities of 98.9% and 92.4%, respectively. The sensitivity of the 
TR-IFMA assay was remarkably high compared to findings observed recently in children 
using commercial ELISA tests, as outlined above.
In study II, only two of the 82 control children were positive for IgA anti-DGP and IgG 
anti-DGP, indicating a specificity as high as 97.6% for both IgA and IgG anti-DGP assays. 
None of the controls were positive for both IgA and IgG anti-DGP. The control children 
were not followed and although these children were tested negative for tTGA, it is pos-
sible that some of these healthy but genetically predisposed children will develop celiac 
disease later on. However, the four positive samples in the control group had relatively 
low levels of IgA or IgG anti-DGP antibodies. We also demonstrated that both the IgA 
and IgG anti-DGP antibody levels correlated with the severity of the villous atrophy in 
the intestinal biopsies (II) emphasizing the importance of high levels of antibodies in the 
diagnosis of celiac disease. 
In study III, altogether 291 children positive for HLA-DQA1*05 and -DQB1*02 alleles 
were followed prospectively for the development of celiac disease-associated antibod-
ies. The cumulative incidence of tTGA seropositivity by the age of 3 to 4 years in this 
cohort was 6.5%, which is in accordance with earlier studies, in which the frequency of 
tTGA seropositivity in genetically predisposed children was reported to vary between 
2.6% and 6.0% at the age of 5 to 7 years (87,161,340,343). The cumulative incidence of 
confirmed celiac disease in our study was 3.1%. Importantly, the majority of the children 
with biopsy-confirmed celiac disease were diagnosed after tTGA seropositivity without 
clinical suspicion, which support the notion that presently many of the children with 
celiac disease are asymptomatic (344). The median age at the time of seroconversion was 
24 months and three of the children seroconverted tTGA positive at the age of 18 months. 
Eight of all 291 children (2.7%) had transient tTGA seropositivity and they turned tTGA 
seronegative during the follow-up. Interestingly, the children with transient tTGA sero-
positivity including one child with a negative biopsy, had significantly lower tTGA titers 
at the time of seroconversion than the nine children who were later confirmed with celiac 
disease by duodenal biopsy, supporting the significance of antibody levels in the diagno-
sis of celiac disease (21). 
In study III, all the children with a high genetic risk for celiac disease who convert-
ed tTGA seropositive and were confirmed with celiac disease were both IgA and IgG 
anti-DGP positive at the time of tTGA seroconversion. Over half of the children with 
transient tTGA seropositivity were also IgG anti-DGP positive at the time of tTGA sero-
conversion but none of them were IgA anti-DGP positive, confirming the high specificity 
of IgA class anti-DGP assay for celiac disease as already shown in study II. Not only 
tTGA seroconverted children but also some of the children who remained tTGA sero-
negative developed anti-DGP antibodies. Altogether 76 of 1151 serum samples analyzed 
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from children who remained tTGA seronegative during the follow-up were positive for 
IgG but only 17 of the children were positive for IgA anti-DGP, with the corresponding 
specificities of 93.4% and 98.5% for IgG and IgA anti-DGP, respectively. The specificities 
of the IgA and IgG anti-DGP assays were more or less similar to those reported in study 
II. Importantly, in the majority of tTGA seronegative children, that were positive for an-
ti-DGP antibodies, only one sample taken during the follow-up was positive, suggest-
ing that transient anti-DGP-positivity is relatively common. However, in children with 
transient positivity to anti-DGP antibodies, the levels were lower than in children with 
confirmed celiac disease. Most of the tTGA seronegative children, repeatedly positive 
for IgG anti-DGP, were positive also at the last sampling point. Since the follow-up time 
was limited, it is possible that some of these repeatedly anti-DGP seropositive children 
will develop celiac disease later on. These findings may be associated with the slightly 
lower specificity of the IgG anti-DGP assay in study III compared to the results of study 
II. Altogether, both of these studies emphasize the significance of the levels of anti-DGP 
antibodies in the diagnosis of celiac disease in pediatric patients.
Since several studies have suggested that the best sensitivity and specificity for diag-
nosis of celiac disease, especially in young children, can be achieved by combining assays 
detecting IgA tTGA and IgG anti-DGP antibodies, we further analyzed whether anti-DGP 
antibodies appeared before tTGA positivity. The earlier appearance of anti-DGP antibod-
ies was demonstrated both retrospectively in the DIPP cohort (II) and prospectively in 
the cohort of children with a high genetic risk for celiac disease (III). In the DIPP cohort, 
anti-DGP antibody positivity preceded tTGA seroconversion in up to 72.9% (35 of 48) of 
children with confirmed celiac disease. In 13 of the children with confirmed celiac disease 
both IgA and IgG anti-DGP antibodies preceded tTGA seroconversion. Only one of the 
children had IgA but not IgG anti-DGP antibodies preceding tTGA positivity. In the DIPP 
cohort the first IgA or IgG anti-DGP seropositivity was detected a median 0.9 or 1.0 year 
earlier than tTGA seropositivity, respectively. In the prospective follow-up study, IgG 
class anti-DGP antibodies appeared a median 1.0 year earlier than tTGA seroconversion 
in over half of the children with confirmed celiac disease. In contrast, IgA class anti-DGP 
positivity preceded tTGA seroconversion only in one child. The results obtained in these 
studies are in line with the only prospective study published so far (30). However, in that 
study, anti-DGP positivity preceded the appearance of tTGA in only 19% of the subjects 
studied, which is a much lower frequency than what was observed in the studies de-
scribed here. Importantly, in the prospective follow-up study, anti-DGP positivity was 
observed to preceed tTGA positivity also in children with transient tTGA seropositivity. 
Therefore, it appears that IgG anti-DGP antibodies perform with a good sensitivity to pre-
dict tTGA seropositivity but they do not clearly discriminate between celiac disease-asso-
ciated and transient tTGA seropositivity. This may complicate the clinical usefulness of 
the phenomenon. As transient tTGA seropositivity has been reported in young children, 
it is similarly possible that anti-DGP positivity may also be a transient phenomenon espe-
cially in young that does not necessarily predict the clinical onset of celiac disease (340). 
6.2 PERIPHERAL BLOOD GLIADIN-SPECIFIC T-CELL RESPONSES
Since it is known that the T-cell mediated inflammation process in the intestinal mucosa 
has already begun when celiac disease-associated antibodies appear, the detection of gli-
adin-specific T-cell responses in peripheral blood could provide an interesting possibility 
for monitoring the celiac disease-associated immune response. Moreover, it is possible 
that the emergence of these peripheral blood T cells might even precede the antibody 
response to gliadin peptides. Gliadin epitopes recognized by CD4+ T cells were first de-
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scribed through an analysis of intestinal T cells (10). Later, it was shown that CD4+ T cells 
specific to deamidated gliadin epitopes can also be detected in the peripheral blood of a 
majority of patients with active celiac disease. The frequency of gliadin-specific CD4+ T 
cells in the circulation is relatively low and thus in most of the studies patients have been 
challenged to oral gluten to enhance the gliadin-specific immune response in the gut, 
which also leads to an increase of gliadin-specific T cells in the circulation (14-16,251). All 
of the studies mentioned above have analyzed gliadin-specific T-cell responses in adult 
patients. Only one recently published study demonstrated that these gliadin-specific T 
cells are detectable also in children with celiac disease, even without gluten challenge 
(87). The Norwegian study group has recently shown that gliadin-specific CD4+ T cells 
are detectable in the circulation of adult patients also without oral gluten challenge by 
using a sensitive HLA class II tetramer technique (252). 
In study I, we demonstrated, for the first time, that CD4+ T cells specific to gTG are 
also detectable in the peripheral blood of children with newly diagnosed celiac disease, 
and that their frequency is higher than that observed in healthy control children. T-cell 
responses to gTG were likewise detected in HLA-DQ2-positive children followed pro-
spectively from the age of 9 months in study III. Peripheral T-cell responses were detected 
more often to gTG than native gliadin in children with active celiac disease. These results 
are in accordance with the model that the deamidation of gliadin epitopes enhances their 
T-cell reactivity in the context of celiac disease-associated HLA molecules (271,345,346). 
The deamidation of gliadin by tTG leads to the conversion of glutamine residues to nega-
tively charged glutamic acid residues, enhancing the capacity of gliadin peptides to bind 
to HLA-DQ2 and -DQ8. Although peripheral blood T-cell responses were detected more 
often to gTG in children with celiac disease, T-cell responses to native gliadin were de-
tected at a similar frequency in children with celiac disease and healthy children with a 
genetic risk for celiac disease (I, III). This is in line with one of the early studies, in which 
peripheral T-cell responses to native gliadin were observed to be common in healthy 
control subjects (347). Moreover, studies by Anderson et al. have shown that some of 
the healthy controls also had specific T-cell responses to native gliadin in the peripheral 
blood after an oral gluten challenge, whereas responses to deamidated gliadin increased 
only in patients with confirmed celiac disease (15). Ráki et al. reported similar results, 
detecting gliadin-specific peripheral blood T cells by HLA tetramers in celiac disease pa-
tients but not in controls after a short-term gluten challenge (16). Finally, in the study by 
Ben-Horin et al., CD4+ memory T-cell responses to deamidated gliadin were detected 
in about half of adult patients on a gluten-free diet (254). Importantly, almost half of the 
patients did not show any reactivity to deamidated gliadin. Also according to our stud-
ies, T-cell responses to native gliadin seems to be relatively common in healthy control 
children (I and III). In our study, CD4+ T-cell responses were detected significantly more 
often to gTG as compared to native gliadin in children with active celiac disease, whereas 
healthy controls recognized native gliadin as often as gTG (I). In healthy controls, T-cell 
responses to gTG were as common in DQ8-positive as they were in DQ2-positive healthy 
controls (I). Thus, healthy individuals carrying the DQ2 and DQ8 alleles do not have 
enhanced T-cell responses to deamidated gliadin epitopes. Taken together, the increased 
T-cell recognition of deamidated gliadin in children with active celiac disease may result 
from an increased amount of gTG-specific memory T cells in the peripheral bllod. Nev-
ertheless, the frequency of gTG-specific memory T-cells appears to be low without oral 
gluten challenge. In study I, 11 of the 20 children with confirmed celiac disease responded 
to gTG (I), which is in accordance with the study by Ben-Horin et al., in which half of the 
patients with celiac disease did not show reactivity to deamidated gliadin using a CFSE 
dilution method (254). 
Peripheral T-cell responses in children with celiac disease and in healthy controls were 
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also tested to the peptides QLQPFPQPELPY (Q12Y) and PQPELPYPQPELPY (P14Y), 
which contain the previously identified immunodominant epitopes of α-gliadin: α-I and 
α-II, respectively (17). Interestingly, none of the patients and only a few of the control 
children recognized these peptides, indicating that these epitopes do not explain the pe-
ripheral blood T-cell reactivity to deamidated gliadin in children. These results are in 
accordance with an earlier study that demonstrated that intestinal T-cell responses in 
children with celiac disease are more variable than in adults, and are directed against 
multiple deamidated gliadin and gluten peptides as well as toward native gluten pep-
tides, instead of the earlier described immunodominant epitopes of α-gliadin (18). Other 
epitopes recognized by intestinal T cells from adult patients have also been characterized 
and these studies demostrate that intestinal T cells in adult patients with celiac disease 
also recognize several epitopes of gliadin and not only the so-called immunodominant 
epitopes (255,256,349). Differences in the T cell epitopes recognized may also be explained 
by the first cereals that are introduced into the diet of Finnish children, usually rye and 
barley together with wheat. Therefore, T-cell responses to wheat gluten may be relatively 
less important in Finnish children and this may explain the absence of T-cell responses to 
the immunodominant epitopes of wheat α-gliadin in our study.
T-cell reactivity to the self-antigen tTG was extremely rare in this study. In study I, 
none of the 16 children with celiac disease, and only two of 55 control children (3.6%), 
showed T-cell responses to tTG, and in study III the T-cell responses to tTG varied be-
tween 0% and 7.9% at different sampling points. Peripheral blood T-cell reactivity to tTG 
was remarkably lower than that reported in earlier studies (223,224). Comerford et al. 
demonstrated T-cell responses to tTG in up to 80% of untreated and in 40% of treated 
adults patients with celiac disease but also in 38% of healthy controls (224). They also 
demonstrated that T cells specific to tTG produced the proinflammatory cytokines IL-17A 
and IL-21, which may have relevance for the pathogenesis of celiac disease.
Both in study I and III, we demonstrated that peripheral blood T cells specific to na-
tive and deamidated gliadin had mainly a memory phenotype and they expressed high 
levels of the gut-homing molecule β7-integrin. The frequency of the memory phenotype 
(CD45RA-CD45RO+) on gTG-specific T cells was higher than on T cells specific for na-
tive gliadin, but only in patients with celiac disease. This finding suggests that in healthy 
children, some of the observed T-cell responses to gliadin and gTG may in fact be derived 
from in vitro-activated naïve T cells, whereas gTG-specific responses in patients with 
celiac disease are more clearly of memory origin. Similar findings were detected in the 
healthy, genetically predisposed children in the prospective follow-up study (III) as no 
difference was observed in the percentages of memory CD4+ T cells between stimulations 
with deamidated and native gliadin. It is known that upon activation and proliferation 
in vitro naïve T cells first acquire the expression of CD45RO and subsequently lose the 
expression of CD45RA, making the timing of the analysis of CD45 molecule expression in 
vitro critically important (204). Regardless of this, it can be assumed that the percentage 
of proliferating CD4+ T cells with the CD45RA-CD45RO+ phenotype more or less reflects 
the frequency of memory cell-derived antigen-specific precursor T cells. Our results are 
in accordance with the study by Ráki et al., which used an elegant HLA-tetramer method 
to visualize CD4+ T cells specific to deamidated gliadin directly ex vivo (16). In most of 
the patients with celiac disease the tetramer-positive cells analyzed were of the CD45RA-
CD45RO+ memory phenotype T cells (16). In our studies, we also observed that gliadin- 
and gTG-specific T cells expressed high levels of the β7-integrin molecule in both children 
with active celiac disease and in children with a genetic risk for celiac disease. This find-
ing supports the hypothesis that peripheral blood CD4+ T cells specific to both native and 
deamidated gliadin are originally activated in the gut and are capable of trafficking back 
to the intestine. 
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6.3 GLUTEN INTRODUCTION 
Since the most important celiac disease risk allele combination of HLA-DQA1*05 and 
-DQB1*02 is relatively common in the general population, it has been suggested that en-
vironmental factors must also have a pivotal role in the development of celiac disease. 
Several studies have suggested that the timing of gluten introduction to infants influences 
the risk of celiac disease in genetically susceptible children (103,160,161,167,168,170). Spe-
cifically, these studies suggest that an optimal window of gluten introduction for preven-
tion of celiac disease exists between 4 and 6 months of age while breastfeeding is ongoing. 
Based on these observations, the secondary aim of this thesis was to evaluate whether the 
timing of gluten introduction has a significant effect on the development celiac disease-as-
sociated immune responses. For this purpose a dietary intervention was performed in 
order to analyze whether gluten introduction has an effect on the development of celiac 
disease-associated antibodies and the development of clinical disease. The dietary inter-
vention group was given special nutrition counseling with the aim of targeting gluten in-
troduction to between 4 and 6 months of age while breastfeeding was ongoing, and start-
ing cereal consumption in small but gradually increasing doses (103,160,161,165,338). The 
control group received the normal advice given to all Finnish families at the child health 
clinics. Approximately half of the children (54%) in the study had gluten introduced to 
their diet within the optimal window 4 and 6 months of age, and this was successful more 
often in the intervention than in the control group. The median age of gluten introduc-
tion in the study was 6.0 months. Although the power of this study is limited due to the 
relatively low number of children studied, neither the timing of gluten introduction nor 
breastfeeding appeared to affect the development of celiac disease or associated autoanti-
bodies. Importantly, our findings are in accordance with the results of recently published 
larger prospective studies (106,172,173). Contrary to the earlier hypothesis, these studies 
did not support the importance of either the age at gluten introduction or concurrent 
breastfeeding in the development of celiac disease (106,172,173).
6.4 LIMITATIONS OF THE STUDY AND FURTHER CHALLENGES 
When looking at the results of this study, certain limitations, which may have had an im-
pact to the conclusions of the study, need to be considered. 
Peripheral blood T-cell responses to deamidated gliadin were not seen in all children 
with active celiac disease, which may, at least partly, be due to the low number of anti-
gen-specific T cells in the circulation. Other methods than the CFSE dilution assay uti-
lized here could be more sensitive in detecting gliadin-specific T cells in the peripheral 
blood, and should be considered in future studies. As described earlier, the gliadin epi-
topes are presented to the CD4+ T cells in the context of HLA-DQ2 or -DQ8 molecules. In 
our studies, we did not directly test whether the peripheral blood gliadin-specific T-cell 
responses observed were HLA-DR or -DQ restricted, which could have allowed a more 
specific analysis of the pattern of T-cell responses in patients and controls. We neither 
tested whether the peripheral blood gliadin-specific T-cell responses differed from their 
cytokine production profiles which could allow for more specific analysis as well. 
Due to the original screening for genetic risk for T1D in the DIPP study, the proportion 
of HLA-DQ8-positive children with celiac disease in study II was higher than observed 
in earlier clinical studies. The control group consisted of healthy age-matched children 
positive for HLA-DQ2 or -DQ8 risk alleles, which may be criticized since healthy children 
may have lower levels of anti-DGP-antibodies than symptomatic subjects with other GI 
or autoimmune diseases than celiac disease, leading to the overestimation of the speci-
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ficity of the assay. Further analysis of the anti-DGP assay with a control group of symp-
tomatic children with normal histological findings in duodenal biopsies would allow the 
calculation of positive and negative predictive values, which would be more useful in the 
clinical evaluation of the performance of the test. 
To analyze the development of gliadin-specific immune responses in study III, blood 
samples were taken from children at the ages of 9, 12, 18 months and every 12 months 
thereafter. The percentage of children with anti-DGP seropositivity, as well as the percent-
age of T-cell responses to deamidated gliadin was relatively high at the age of 9 months. 
As no earlier samples were taken, it remains unclear whether the gliadin-specific immune 
responses could be detectable even earlier and whether they are induced by the introduc-
tion of gluten. As the primary aim of the study was to analyze whether the gliadin-specif-
ic immune response could be detected by immunological tests before the damage of the 
intestinal mucosa and the clinical onset of the disease, the duodenal biopsy should had 
been performed at the time of anti-DGP seropositivity or at least after repeated anti-DGP 
positivity. Peripheral blood T-cell responses were analyzed only in 85 of the children and 
thus the analysis of the correlation between the development of T-cell responses to gli-
adin, the appearance of tTGA and anti-DGP antibodies and the clinical disease was not 
feasible. In the future, a larger study population and possibly more frequent sampling 
would be needed for a full evaluation of the significance of peripheral blood T-cell re-
sponses to deamidated gliadin in pediatric patients. 
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7 Conclusions
In conclusion, our studies demonstrate that the TR-IFMA assay for detecting antibodies 
to a synthetic deamidated gliadin peptide performs with a high sensitivity and specific-
ity in the diagnosis of celiac disease in pediatric patients. Moreover, we demonstrated, 
first retrospectively that specifically IgG anti-DGP antibodies appeared a median 1.0 year 
earlier than IgA tTGA in the majority of the children with celiac disease. In the follow-up 
study of children with a high genetic risk for celiac disease, altogether 6.5% of children 
converted tTGA seropositive by the age of 4 years and the final incidence of celiac disease 
was 3.1%. Anti-DGP antibodies also preceded tTGA seropositivity a median 1.0 year ear-
lier in this study. This was observed both in the children with confirmed celiac disease 
as well as those with transient tTGA seropositivity. Collectively, the results from our two 
studies indicate that an earlier detection of celiac disease may be possible by monitoring 
tTGA and anti-DGP antibodies frequently in genetically susceptible children. 
In these studies, we also demonstrate for the first time that CD4+ T cells specific to de-
amidated gliadin are detectable in the peripheral blood of children with newly diagnosed 
celiac disease and also in the blood of children with a high genetic risk for celiac disease 
already in early infancy. Although responses to gTG were observed both in children with 
celiac disease and in healthy but genetically predisposed children, they were significantly 
less common in the latter group. Deamidation of gliadin increased the frequency of T-cell 
responses in children with active celiac disease, whereas the responses to deamidated and 
native gliadin did not differ in healthy controls. In the follow-up study, T-cell responses 
to gTG were relatively common already at an early age of 12 months in HLA-DQ2-posi-
tive children but the frequency of responses decreased during the follow-up to a similar 
level that was observed in the healthy control children in study I. In both children with 
celiac disease as well as in healthy children with a genetic risk for celiac disease, CD4+ 
T cells specific to gTG appeared to have a memory phenotype and they expressed the 
gut-homing marker, β7-integrin. In all, our results support the widely accepted model for 
the importance of T-cell responses to deamidated gliadin epitopes in the pathogenesis of 
celiac disease also in pediatric patients. Based on our results, it seems that responses to 
gTG are relatively common at an early age in genetically predisposed children, but they 
appear to gradually decrease in children who remain healthy whereas they increase in 
those who develop celiac disease.
Although the power of the follow-up study was limited, our results support the notion 
that neither the timing of gluten introduction nor breastfeeding affects the development 
of celiac disease-associated autoimmunity. Importantly, these results are in accordance 
with other large prospective studies that have been published recently (106,172,173) .
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The aim of this thesis was to analyze, 
by using immunological methods, 
whether gliadin-specific immune 
responses can be detected prior to the 
development of the clinical phase of 
celiac disease. Our results indicate 
that earlier detection of celiac disease 
in genetically susceptible children 
may be possible by monitoring tTGA 
and anti-DGP antibodies whereas 
monitoring peripheral blood gliadin-
specific T-cell responses did not 
enhance early diagnosis. Anti-DGP 
antibodies may be the first marker 
of celiac disease in a majority of 
pediatric patients.
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